

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 689 610 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**03.07.2002 Bulletin 2002/27**

(51) Int Cl.7: **C12Q 1/68, G01N 33/48**

(86) International application number:  
**PCT/US94/02938**

(21) Application number: **94911643.8**

(87) International publication number:  
**WO 94/21822 (29.09.1994 Gazette 1994/22)**

(22) Date of filing: **18.03.1994**

(54) **DNA SEQUENCING BY MASS SPECTROMETRY VIA EXONUCLEASE DEGRADATION**

**DNS-SEQUENZBESTIMMUNG DURCH MASSENSPEKTROMETRIE AUF DEM WEG DES  
ABBAUS MIT EXONUKELEASE**

**SEQUENCAGE DE L'ADN AU MOYEN DE LA SPECTROMETRIE DE MASSE PAR DEGRADATION  
A L'EXONUKELEASE**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE**

(74) Representative: **Baldock, Sharon Claire et al**  
**BOULT WADE TENNANT,**  
**Verulam Gardens**  
**70 Gray's Inn Road**  
**London WC1X 8BT (GB)**

(30) Priority: **19.03.1993 US 34738**

(56) References cited:  
**EP-A- 0 371 437 EP-A- 0 612 994**  
**WO-A-89/03432 WO-A-89/12694**  
**WO-A-90/11369 WO-A-92/01812**  
**US-A- 5 288 644**

(43) Date of publication of application:  
**03.01.1996 Bulletin 1996/01**

(73) Proprietor: **SEQUENOM, INC.**  
**San Diego, California 92121 (US)**

(72) Inventor: **Köster, Hubert**  
**Lugano-Cassarate, CH 6900 (CH)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 689 610 B1**

## Description

- [0001] The fundamental role that determining DNA sequences has for the life sciences is evident. Its importance in the human genome project has been discussed and published widely [e.g. J.E. Bishop and M. Waldholz, 1991, *Genome. The Story of the Most Astonishing Scientific Adventure of Our Time - The Attempt to Map All Genes in the Human Body*, Simon & Schuster, New York].
- [0002] The current state-of-the-art in DNA sequencing is summarized in recent review articles [e.g. B. Barrell, *The FASEB Journal*, 5, 40 (1991); G.L. Trainor, *Anal. Chem.* 62, 418 (1990), and references cited therein]. The most widely used DNA sequencing chemistry is the enzymatic chain termination method [F. Sanger et al., *Proc. Natl. Acad. Sci. USA*, 74, 5463 (1977)] which has been adopted for several different sequencing strategies. The sequencing reactions are either performed in solution with the use of different DNA polymerases, such as the thermophilic Taq DNA polymerase [M.A. Innes, *Proc. Natl. Acad. Sci. USA*, 85, 9436 (1988)] or specially modified T7 DNA polymerase ("SEQUENASE") [S. Tabor and C.C. Richardson, *Proc. Natl. Acad. Sci. USA*, 84, 4767 (1987)], or in conjunction with the use of polymer supports. See for example S. Stahl et al., *Nucleic Acids Res.*, 16, 3025 (1988); M. Uhlen, PCT Application WO 89/09282; Cocuzza et al., PCT Application WO 91/11533; and Jones et al., PCT Application WO 92/03575.
- [0003] A central, but at the same time limiting, part of almost all sequencing strategies used today is the separation of the base-specifically terminated nested fragment families by polyacrylamide gel electrophoresis (PAGE). This method is time-consuming and error prone and can result in ambiguous sequence determinations. As a consequence of the use of PAGE, highly experienced personnel are often required for the interpretation of the sequence ladders obtained by PAGE in order to get reliable results. Automatic sequence readers very often are unable to handle artifacts such as "smiling", compressions, faint ghost bands, etc. This is true for the standard detection methods employing radioactive labeling such as  $^{32}\text{P}$ ,  $^{33}\text{P}$  or  $^{35}\text{S}$ , as well as for the so-called Automatic DNA Sequencers (e.g. Applied Biosystems, Millipore, DuPont, Pharmacia) using fluorescent dyes for the detection of the sequencing bands.
- [0004] Apart from the time factor the biggest limitation of all methods involving PAGE as an integral part, however, is the generation of reliable sequence information, and the transformation insert of this information into a computer format to facilitate sophisticated analysis of the sequence data utilizing existing software and DNA sequence and protein data banks.
- [0005] With standard Sanger sequencing 200 to 500 bases of unconfirmed sequence information could be obtained in about 24 hours; with automatic DNA sequencers this number could be multiplied by approximately a factor of 10 to 20 due to processing several samples simultaneously. A further increase in throughput could be achieved by employing multiplex DNA sequencing [G. Church et al., *Science*, 240, 185-188 (1988); Köster et al., *Nucleic Acids Res. Symposium Ser. No. 24*, 318-21 (1991)] in which, by using a unique tag sequence, several sequencing ladders could be detected one after the other from the same PAGE after blotting, UV-crosslinking to a membrane, and hybridizations with specific complementary tag probes. However, this approach is still very laborious, often requires highly skilled personnel and can be hampered by the use of PAGE as a key element of the whole process.
- [0006] A large scale sequencing project often starts with either a cDNA or genomic library of large DNA fragments inserted in suitable cloning vectors such as cosmid, plasmid (e.g. pUC), phagemid (e.g. pEMBL, pGEM) or single-stranded phage (e.g. M13) vectors [T. Maniatis, E.F. Fritsch and J. Sambrook (1982) *Molecular Cloning. A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.; *Methods in Enzymology*, Vol. 101 (1983), Recombinant DNA, Part C; Vol. 153 (1987), Recombinant DNA, Part D; Vol. 154 (1987), Recombinant DNA, Part E; Vol. 155 (1987), Recombinant DNA, Part F and Vol. 152 (1987), *Guide to Molecular Cloning Techniques*, Academic Press, New York]. Since large DNA fragments currently cannot be sequenced directly in one run because the Sanger sequencing chemistry allows only about 200 to 500 bases to be read at a time, the long DNA fragments have to be cut into shorter pieces which are separately sequenced. In one approach this is done in a fully random manner by using, for example, unspecific DNase I digestion, frequently cutting restriction enzymes, or sonification, and sorting by electrophoresis on agarose gels [*Methods in Enzymology*, *supra*]. However, this method is time-consuming and often not economical as several sequences are sequenced many times until a contiguous DNA sequence is obtained. Very often the expenditure of work to close the gaps of the total sequence is enormous. Consequently, it is desirable to have a method which allows sequencing of a long DNA fragment in a non-random, i.e., direct, way from one end through to the other. Several strategies have been proposed to achieve this [*Methods in Enzymology*, *supra*; S. Henikoff, *Gene*, 28, 351-59 (1984); S. Henikoff, et al. US Patent No. 4,843,003; and PCT Application WO 91/12341]. However, none of the currently available sequencing methods provide an acceptable method of sequencing megabase DNA sequences in either a timely or economical manner. The main reason for this stems from the use of PAGE as a central and key element of the overall process.
- [0007] In PAGE, under denaturing conditions the nested families of terminated DNA fragments are separated by the different mobilities of DNA chains of different length. A closer inspection, however, reveals that it is not the chain length alone which governs the mobility DNA chains by PAGE, but there is a significant influence of base composition on the mobility [R. Frank and H. Koster, *Nucleic Acids Res.*, 6, 2069 (1979)]. PAGE therefore is not only a very slow, but also

an unreliable method for the determination of molecular weights, as DNA fragments of the same length but different sequence/base composition could have different mobilities. Likewise, DNA sequences which have the same mobility could have different sequence/base compositions.

[0008] The most reliable way for the determination of the sequence/base composition of a given DNA fragment would therefore be to correlate the sequence with its molecular weight. Mass spectrometry is capable of doing this. The enormous advantage of mass spectrometry compared to the above mentioned methods is the speed, which is in the range of seconds per analysis, and the accuracy of mass determination, as well as the possibility to directly read the collected mass data into a computer. The application of mass spectrometry for DNA sequencing has been investigated by several groups [e.g. Methods in Enzymology, Vol. 193: Mass Spectrometry, (J.A. McCloskey, editor), 1990, Academic Press, New York; K.H. Schramm Biomedical Applications of Mass Spectrometry, 34, 203-287 (1990); P.F. Crain Mass Spectrometry Reviews, 9, 505 (1990)].

[0009] Most of the attempts to use mass spectrometry to sequence DNA have used stable isotopes for base-specific labeling, as for instance the four sulfur isotopes  $^{32}\text{S}$ ,  $^{33}\text{S}$ ,  $^{34}\text{S}$  and  $^{36}\text{S}$ . See, for example, Brennan et al., PCT Application WO 89/12694, R.L. Mills United States Patent No. 5,064,754, United States Patent No. 5,002,868, Jacobson et al.; Hean European Patent Application No. A1 0360676. Most of these methods employ the Sanger sequencing chemistry and - which jeopardizes to some extent the advantages of mass spectrometry - polyacrylamide gel electrophoresis with some variations such as capillary zone electrophoresis (CZE) to separate the nested terminated DNA fragments prior to mass spectrometric analysis.

[0010] One advantage of PAGE is the property of being a parallel method, i.e., several samples could be analyzed simultaneously (though this is not true for CZE which is a serial method), whereas mass spectrometry allows, in general, only a serial handling of the samples. Mass spectrometric DNA sequencing may be carried out without the use of PAGE, employing desorption/ionization techniques applicable to larger biopolymers such as electrospray (ES) [J.B. Fenn et al., J. Phys. Chem., 88, 4451-59 (1984); Fenn et al., PCT Application No. WO 90/14148; and B. Ardrey, Spectroscopy Europe, 4, 10-18 (1992)] and matrix assisted laser desorption/ionization (MALDI) mass spectrometry [F. Hillenkamp et al., Laser Desorption Mass Spectrometry, Part I: Mechanisms and Techniques and Part II: Performance and Application of MALDI of Large Biomolecules, in Mass Spectrometry in the Biological Sciences: A Tutorial (M.L. Gross, editor), 165-197 (1992), Kluwer Academic Publishers, The Netherlands] which can facilitate determination of DNA sequences by direct measurement of the molecular masses in the mixture of base-specifically terminated nested DNA fragments. By integrating the concept of multiplexing through the use of mass-modified nucleoside triphosphate derivatives, the serial mode of analysis typical for current mass spectrometric methods can be changed to a parallel mode.

[0011] Sequencing of oligonucleotides using matrix assisted laser desorption mass spectrometry is described in EP-A-0612994 which forms state of the art by virtue of Article 54(3)(EPC). In this disclosure oligonucleotides are degraded nucleotide by nucleotide from the 3' end and the 5' end to produce a mixture of oligonucleotides of varying length. The oligonucleotides are then mixed with a material which acts as a suitable matrix and the molecular weight of each oligonucleotide determined by mass spectrometry. The identity of the nucleotide removed from the oligonucleotide by exonuclease digestion is inferred from the molecular weight of the remaining oligonucleotides.

[0012] MALDI and ES mass spectrometry are in some aspects complementary techniques. While ES, using an atmospheric pressure ionization interface (API), can accommodate continuous flow streams from high-performance liquid chromatographs (HPLC) [K.B. Tomer, et al. Biological Mass Spectrometry, 20, 783-88(1991)] and capillary zone electrophoresis (CZE) [R.D. Smith et al., Anal. Chem., 60, 436-41 (1988)] this is currently not available for MALDI mass spectrometry. On the other hand, MALDI mass spectrometry is less sensitive towards buffer salts and other low molecular weight components in the analysis of larger molecules with a TOF mass analyzer [Hillenkamp et al. (1992), supra]; In contrast ES is very sensitive towards by-products of low volatility. While the high mass range in ES mass spectrometry is accessible through the formation of multiply charged molecular ions, this is achieved in MALDI mass spectrometry by applying a time-of-flight (TOF) mass analyzer and the assistance of an appropriate matrix to volatilize the biomolecules. Similar to ES, a thermospray interface has been used to couple HPLC on-line with a mass analyzer. Nucleosides originating from enzymatic hydrolysates have been analyzed using such a configuration [C.G. Edmonds et al. Nucleic Acids Res., 13, 8197-8206 (1985)]. However, Edmonds et al. does not disclose a method for nucleic acid sequencing.

[0013] A complementary and completely different approach to determine the DNA sequence of a long DNA fragment would be to progressively degrade the DNA strand using exonucleases from one side - nucleotide by nucleotide. This method has been proposed by Jett et al. See J.H. Jett et al. J. Biomolecular Structure & Dynamics, 7, 301-309 (1989); and J.H. Jett et al. PCT Application No. WO 89/03432. A single molecule of a DNA or RNA fragment is suspended in a moving flow stream and contacted with an exonuclease which cleaves off one nucleotide after the other. Detection of the released nucleotides is accomplished by specifically labeling the four nucleotides with four different fluorescent dyes and involving laser induced flow cytometric techniques.

[0014] However strategies which use a stepwise enzymatic degradation process can suffer from the problem that



5 this process is difficult to synchronize, i.e., the enzymatic reaction soon comes out of phase. Jett et al., *supra*, have attempted to address this problem by degrading just one single DNA or RNA molecule by an exonuclease. However, this approach is very hard, as handling a single molecule, keeping it in a moving flow stream, and achieving a sensitivity of detection which clearly identifies one single nucleotide are only some of the very difficult technical problems to be solved. In addition, in using fluorescent tags, the physical detection process for a fluorescent signal involves a time factor difficult to control and the necessity to employ excitation by lasers can cause photo-bleaching of the fluorescent signal.

10 [0015] The invention described here addresses most of the problems described above inherent to currently existing DNA sequencing processes and provides chemistries and systems suitable for high-speed DNA sequencing a prerequisite to tackle the human genome (and other genome) sequencing projects.

#### Summary Of The Invention

15 [0016] In contrast to most sequencing strategies, the process of this invention does not use the Sanger sequencing chemistry, polyacrylamide gel electrophoresis or radioactive, fluorescent or chemiluminescent detection. Instead the process of the invention adopts a direct sequencing approach, beginning with large DNA fragments cloned into conventional cloning vectors, and based on mass spectrometric detection. To achieve this, the DNA is by means of protection, specificity of enzymatic activity, or immobilization, unilaterally degraded in a stepwise manner via exonuclease digestion and the nucleotides or derivatives detected by mass spectrometry.

20 [0017] Thus, in accordance with a first aspect the invention provides a method of determining a sequence of a nucleic acid, comprising

- (i) isolating the nucleic acid to be sequenced;
- 25 (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to sequentially release individual nucleotides;
- (iii) measuring the mass of each of the sequentially released nucleotides by mass spectrometry to indicate the identity thereof; and
- (iv) determining the sequence of the nucleic acid from the identified nucleotides.

30 [0018] In a second aspect the invention provides a method of determining a sequence of a nucleic acid, comprising

- (i) isolating the nucleic acid to be sequenced;
- 4 (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to produce a set of nested nucleic acid fragments;
- 35 (iii) identifying the molecular weight value of each one of the set of nucleic acid fragments by mass spectrometry; and
- (iv) determining the sequence of the nucleic acid from the molecular weight values of the set of nucleic acid fragments.

40 [0019] Optionally in such a method the isolated nucleic acid fragment is immobilized by covalent attachment to a solid support.

[0020] The invention also provides kits and systems suitable for carrying out the aforementioned methods.

45 [0021] Prior to this enzymatic degradation, sets of ordered deletions can be created which span the whole sequence of the cloned DNA fragment. In this manner, mass-modified nucleotides can be incorporated using a combination of exonuclease and DNA/RNA polymerase. This enables either multiplex mass spectrometric detection, or modulation of the activity of the exonuclease so as to synchronize the degradative process. In another embodiment of the invention the phasing problem can be resolved by continuously applying small quantities of the enzymatic reaction mixture onto a moving belt with adjustable speed for mass spectrometric detection. In yet another embodiment of the invention, the throughput could be further increased by applying reaction mixtures from different reactors simultaneously onto the moving belt. In this case the different sets of sequencing reactions can be identified by specific mass-modifying labels attached to the four nucleotides. Two-dimensional multiplexing can further increase the throughput of exonuclease mediated mass spectrometric sequencing as being described in this invention.

#### Brief Description Of The Drawings

55 [0022] The accompanying drawings form a part of the specifications and serve the purpose of providing examples illustrating certain embodiments of the present invention. Together with the description they help to explain the principles of the invention without limiting the scope of it.

[0023] FIGURE 1 illustrates a process of exonuclease sequencing beginning with a single-stranded nucleic acid.

[0024] FIGURE 2 illustrates a process similar to FIGURE 1, however, starting with a target nucleic acid inserted into a double-stranded vector.

5 [0025] FIGURE 3 illustrates a method for introducing mass-modified nucleotides into a target nucleic acid sequence multiplexing mass spectrometry.

[0026] FIGURE 4A and 4B illustrate methods for introducing mass-modified nucleotides into a target nucleic acid sequence multiplexing mass spectrometry.

[0027] FIGURE 5 shows positions within a nucleic acid molecule which can be modified for the introduction of discriminating mass increments or modulation of exonuclease activity.

10 [0028] FIGURE 6 illustrates various structures of modified nucleoside triphosphates useful for the enzymatic incorporation of mass-modified nucleotides into the DNA or RNA to be sequenced.

[0029] FIGURE 7 shows some possible functional groups (R) useful to either mass-modification of nucleotides in discrete increments for differentiation by mass spectrometry and/or to modulate the enzymatic activity of an exonuclease.

15 [0030] FIGURE 8 illustrates some linking groups X for the attachment of the mass modifying functionality R to nucleosides.

[0031] FIGURE 9 is a schematic drawing of a sequencing reactor system.

[0032] FIGURE 10 is a graphical representation of idealized output signals following the time-course of the stepwise mass spectrometric detection of the exonucleolytically released nucleotides.

20 [0033] FIGURE 11 illustrates specific labels introduced by mass modification to facilitate multiplex exonuclease mass spectrometric sequencing.

[0034] FIGURE 12 is a schematic drawing of a moving belt apparatus for delivering single or multiple tracks of exonuclease samples for laser induced mass spectrometric sequence determination in conjunction with the sequencing reactor of FIGURE 9.

25 [0035] FIGURE 13 is a schematic representation of individually labeled signal tracks employed in multiplex exonuclease mediated mass spectrometric sequencing.

[0036] FIGURES 14A and 14B illustrate a method for double-stranded exonuclease sequencing for mass spectrometric sequence determination.

### 30 Detailed Description Of The Invention

[0037] The starting point for the process of the invention can be, for example, DNA cloned from either a genomic or cDNA library, or a piece of DNA isolated and amplified by polymerase chain reaction (PCR) which contains a DNA fragment of unknown sequence. Libraries can be obtained, for instance, by following standard procedures and cloning vectors [Maniatis, Fritsch and Sambrook (1982), *supra*; Methods in Enzymology, Vol. 101 (1983) and Vol. 152-155 (1987), *supra*]. Appropriate cloning vectors are also commercially available. As will be apparent, the invention is not limited to the use of any specific vector constructs and cloning procedures, but can be applied to any given DNA fragment whether obtained, for instance, by cloning in any vector or by the Polymerase Chain Reaction (PCR). The unknown DNA sequence can be obtained in either double-stranded form using standard PCR or in a single-stranded form employing asymmetric PCR [PCR Technology: Principles and Applications for DNA Amplification (Erich, editor), M. Stockton Press, New York (1989)].

40 [0038] For those skilled in the art it is clear that both DNA and RNA can be exonucleolytically degraded from either the 5' or 3' end depending upon the choice of exonuclease. Similarly the sequence of an unknown DNA molecule can be determined directly by exonuclease digestion, or alternatively, the DNA fragment of unknown sequence can be transcribed first into a complementary RNA copy which is subsequently exonucleolytically degraded to provide the RNA sequence. Appropriate vectors, such as the pGEM (Promega) vectors, are useful in the present as they have specific promoters for either the SP6 or T7 DNA dependent RNA polymerases flanking the multiple cloning site. This feature allows transcription of both unknown DNA strands into complementary RNA for subsequent exonuclease sequencing. Furthermore, these vectors, belonging to the class of phagemid vectors, provide means to generate single stranded DNA of the unknown double stranded DNA. Thus, by using two vectors which differ only in the orientation of the f1 origin of replication, both strands of the unknown DNA sequence can be obtained in a single stranded form and utilized for subsequent exonuclease sequencing. The scope of the invention is also not limited by the choice of restriction sites. There is, however, a preference for rare cutting restriction sites to keep the unknown DNA fragment unfragmented during the manipulations in preparation for exonuclease sequencing. The following description and the FIGURES do serve the purpose by way of examples to illustrate the principles of the invention. Variations which are within the scope of the invention will be obvious to those skilled in the art. Various mass spectrometric configurations are within the scope of the invention: For desorption/ionization e.g. fast atomic bombardment (FAB), plasma desorption (PD), thermospray (TS) and preferentially

electrospray (ES) and laser desorption with and without an appropriate matrix (LD or MALDI); as mass analyzer e.g. a time-of-flight (TOF) configuration or a quadrupole is applicable.

(i) Preparation of unknown nucleic acid sequence for exonuclease sequencing:

5

[0039] FIGURE 1 describes the process for a single stranded DNA insert ("Target DNA") of a single stranded circular cloning vector. The boundaries of the target DNA are designated A and B. The target DNA, as illustrated in FIGURE 1, has been cloned into the Not I site of a vector. A synthetic oligodeoxynucleotide [N.D. Sinha, J. Biernat, J. McManus and H. Köster, *Nucleic Acids Res.*, 12, 4539 (1984)] which will restore the Not I site to double-strandedness and which is complementary to the vector sequence flanking the A boundary of the insert DNA is hybridized to that site and cleaved by Not I restriction endonuclease. The two pieces of the synthetic oligodeoxynucleotide can then be removed by molecular sieving, membrane filtration, precipitation, or other standard procedures.

10

[0040] FIGURE 1 also illustrates a set of ordered deletions ( $t^0$ ,  $t^1$ ,  $t^2$ ,  $t^3$ ) which can be obtained by the time-limited action of an exonuclease, e.g. T4 DNA polymerase, in the absence of dNTPs. The set of deletions can be immobilized on a solid support Tr ( $Tr^0$ ,  $Tr^1$ ,  $Tr^2$ ,  $Tr^3$ ), or alternatively, the set of ordered deletions can be obtained in a heterogeneous reaction by treating the solid support  $Tr^0$  containing the complete target DNA sequence with an exonuclease in a time-limited manner. In the instance where the 3' termini of each time point are too heterogeneous (i.e., "fuzzy") to be analyzed directly by exonuclease mediated mass spectrometric sequencing, circularization of the template and a cloning step can be performed prior to this sequencing process with single transformed colonies selected.

15

[0041] A single stranded linear DNA fragment carrying the unknown sequence with its A boundary at the 3' end can be directly sequenced by an 3' exonuclease in an apparatus described below and schematically depicted in FIGURE 9, provided that the exonuclease is immobilized within the reactor on, for example, beads, on a frit, on a membrane located on top of the frit or on the glass walls of a capillary or entrapped in a gel matrix or simply by a semipermeable membrane which keeps the exonuclease in the reactor while the linear DNA fragment is circulating through a loop.

20

[0042] At time intervals, or alternatively as a continuous stream, the reaction mixture containing the buffer and the released nucleotides is fed to the mass spectrometer for mass determination and nucleotide identification. In another embodiment, the stream containing the nucleotides released by exonuclease action can be passed through a second reactor or series of reactors which cause the released nucleotide to be modified. For example, the second reactor can contain an immobilized alkaline phosphatase and the nucleotides passing therethrough are transformed to nucleosides prior to feeding into the mass spectrometer. Other mass-modifications are described below.

25

[0043] In general, when it is the released nucleotide (or ribonucleotide) which is mass-modified, the modification should take as few steps as possible and be relatively efficient. For example, reactions used in adding base protecting groups for oligonucleotide synthesis can also be used to modify the released nucleotide just prior to mass spectrometric analysis. For instance, the amino function of adenine, guanine or cytosine can be modified by acylation. The amino acyl function can be, by way of illustration, an acetyl, benzoyl, isobutyryl or anisoyl group. Benzoylchloride, in the presence of pyridine, can acylate the adenine amino group, as well as the deoxyribose (or ribose) hydroxyl groups. As the glycosidic linkage is more susceptible to hydrolysis, the sugar moiety can be selectively deacylated if the acyl reaction was not efficient at those sites (i.e., heterogeneity in molecular weight arising from incomplete acylation of the sugar). The sugar moiety itself can be the target of the mass-modifying chemistry. For example, the sugar moieties can be acylated, tritylated, monomethoxytritylated, etc. Other chemistries for mass-modifying the released nucleotides (or ribonucleotides) will be apparent to those skilled in the art.

35

[0044] In another embodiment the linear single stranded DNA fragment can be anchored to a solid support. This can be achieved, for example, by covalent attachment to a functional group on the solid support, such as through a specific oligonucleotide sequence which involves a spacer of sufficient length for the ligase to react and which is covalently attached via its 5' end to the support (FIGURE 1). A splint oligonucleotide with a sequence complementary in part to the solid bound oligonucleotide and to the 5' end of the linearized single stranded vector DNA allows covalent attachment of the DNA to be sequenced to the solid support. After annealing, ligation (i.e., with T4 DNA ligase) covalently links the solid bound oligonucleotide and the DNA to be sequenced. The splint oligonucleotide can be subsequently removed by a temperature jump and/or NaOH treatment, or washed off the support using other standard procedures. The solid support with the linear DNA example is transferred to the reactor (FIGURE 9) and contacted with an exonuclease in solution. As illustrated, where the 3' end of the unknown DNA fragment is exposed (ie unprotected), a 3' exonuclease is employed. The released nucleotides, or modified nucleotides if intermediately contacted with a modifying agent such as alkaline phosphatase, are identified by mass spectrometry as described above. Other linking groups are described herein, and still others will be apparent to those skilled in the art from the invention described here.

45

[0045] The solid supports can be of a variety of materials and shapes, such as beads of silica gel, controlled pore glass, cellulose, polyacrylamide, sepharose, sephadex, agarose, polystyrene and other polymers, or membranes of polyethylene, polyvinylidene difluoride (PVDF) and the like. The solid supports can also be capillaries, as well as frits from glass or polymers. Various 3' exonucleases can be used, such as phosphodiesterase from snake venom, Exo-

55



nuclease VII from *E. coli*, Bal 31 exonuclease and the 3'-5' exonuclease activity of some DNA polymerases exerted in the absence of dNTPs, as for example T4 DNA polymerase.

5 [0046] In using a phagemid vector with an inverted f1 origin of replication, the B boundary would be located at the 3' end of the immobilized linear single stranded DNA and exposed to exonuclease sequencing using the same restriction endonuclease, hybridizing oligodeoxynucleotide and splint oligonucleotide. As another embodiment of this invention, the hybridizing oligonucleotide can also be designed to bind a promoter site upstream of the A boundary and by doing so restoring the doublestranded promoter DNA. Directly, or with a short initiator oligonucleotide carrying an attachment functionality at the 5' end, transcription can be initiated with the appropriate specific DNA dependent RNA polymerase [Methods in Enzymology, Vol. 185, Gene Expression Technology (1990); J.F. Milligan, D.R. Groebe, G.W. Witherell and O.C. Uhlenbeck, *Nucleic Acids Res.*, 15, 8783-98 (1987); C. Pitulle, R.G. Kleineldam, B. Sproat and G. Krupp, *Gene*, 112, 101-105 (1992). The RNA transcript can be transferred to the reactor (FIGURE 9) and contacted with an immobilized or otherwise contained exonuclease, or immobilized via the 5' functionality of the initiator oligonucleotide incorporated in the RNA transcript to a solid support and then contacted with an exonuclease in solution.

15 [0047] Depending on the length of the DNA insert (i.e., number of nucleotides between boundary A and B in FIGURE 1) the mass spectrometric exonuclease sequencing process can allow the complete sequence from A to B to be determined in one run. Alternatively, prior to exonuclease sequencing, a set of ordered deletions can be prepared according to standard procedures [e.g. *Methods in Enzymology*, Vol. 101 (1983) and Vol. 152-155 (1987); R.M.K. Dale et al., *Plasmid*, 13, 31-40 (1985)], such that, in FIGURE 1 the steps Tr<sup>0</sup> to Tr<sup>3</sup> can represent either different time values of the mass spectrometric exonuclease sequencing reaction from immobilized DNA fragments or different starting points for the exonuclease DNA/RNA mass spectrometric sequencing process. In either case the principle of the invention described provides a process by which the total sequence of the insert can be determined.

20 [0048] In another embodiment of the invention the unknown DNA sequence (target DNA) is inserted into a double-stranded cloning vector (FIGURE 2) or obtained in double-stranded form, as for example by a PCR (polymerase chain reaction) process [PCR Technology, (1989) supra]. The DNA to be sequenced is inserted into a cloning vector, such as ligated into the Not I site as illustrated in Figure 2. Adjacent to the A boundary there can be located another cutting restriction endonuclease site, such as an Asc I endonuclease cleavage site. The double-stranded circular molecule can be linearized by treatment with Asc I endonuclease and ligated to a solid support using a splint oligodeoxynucleotide (and ligase) as described above which restores the Asc I restriction site (Tr<sup>0</sup>ds and Tr<sup>0</sup>ds). The strand which is not immobilized can be removed by subjecting the double stranded DNA to standard denaturing conditions and washing, thereby generating single-stranded DNAs immobilized to the solid support (Tr<sup>0</sup>ss and Tr<sup>0</sup>ss). Since the unknown double-stranded DNA sequence can be ligated in either orientation to the support there can exist two non-identical 3' termini (+ and - strand) immobilized, which can result in ambiguous sequencing data. The immobilized fragment which carries the vector DNA sequence at the 3' end (Tr<sup>0</sup>ss) can be protected from 3' exonuclease degradation during the sequencing process by, for example, annealing with an oligodeoxynucleotide complementary to the 3' end of the strand to be protected. As there can only be hybridization at one 3' terminus, i.e., to the wrong single-stranded DNA with (-) strand information (Tr<sup>0</sup>ss), some alpha-thio dNTP's can be incorporated into the immobilized (-) strand via treatment with a DNA polymerase and completely protect that strand from exonucleolytic degradation [P.M.J. Burgers and F. Eckstein, *Biochemistry*, 18, 592 (1979); S. Labeit, H. Lehrach and R.S. Goody, *DNA*, 5, 173 (1986); S. Labeit, H. Lehrach and R.S. Goody in *Methods in Enzymology*, Vol. 155, page 166 (1987), supra]. If desired, after incorporation of exonuclease resistant nucleotides, the oligonucleotide primer may be removed by a washing step under standard denaturing conditions. The immobilized single-stranded DNAs are transferred to the sequencing reactor (FIGURE 9) and the sample with the unknown sequence at the 3' end is degraded by an exonuclease in a stepwise manner. The liberated nucleotides, or optionally modified nucleotides, are continuously fed into the mass spectrometer to elucidate the sequence.

35 [0049] As above, where the inserted DNA is too long for determining the complete sequence information between the boundaries A and B (FIGURE 2) in one run of exonuclease mass spectrometric sequencing, a series of overlapping ordered deletions can be constructed according to standard procedures, e.g. utilizing the restriction site RIII producing 3' sticky ends inert towards exonuclease III digestion [Methods in Enzymology, Vol 152-155 (1987) and S. Henikoff, *Gene*, (1984), supra]. When required, the deletion mutants can be recircularized and used to transform host cells following standard procedures. Single colonies of the transformed host cells are selected, further proliferated, and the deletion mutant isolated and immobilized as single-stranded DNAs, similar to the process described above and subsequently analyzed by exonuclease mass spectrometric sequencing. Alternatively, the immobilized full length single stranded DNA (Tr<sup>0</sup>ss) can be treated in time-limited reactions with an exonuclease such as T4 DNA polymerase in the absence of NTPs, to create a set of immobilized ordered deletions for subsequent exonuclease mass spectrometric sequencing. However, in case the 3' termini are too heterogeneous for direct mass spectrometric exonuclease sequencing an intermediate cloning step can be included. In yet another embodiment, the exonuclease mediated sequencing can be performed by providing the single-stranded (ss) nucleic acid fragment in solution. This can be achieved by treating the solid support, e.g. Tr<sup>0</sup>ss, with an oligonucleotide complementary to the unique Asc I site. After hybrid-

ization this site is now double-stranded (ds) and susceptible to Asc I endonuclease cleavage and release of the single-stranded fragment.

[0050] If a cloning vector such as one of the pGEM family (Promega Corp.) is used, both strands of the double-stranded target DNA can be transcribed separately dependant upon which of the specific promoters flanking the insertion site is used (located next to the A or B boundary of the insert, FIGURE 2) and the corresponding specific DNA dependent RNA polymerase (i.e., SP6 or T7 RNA polymerase). These RNA transcripts can be directly transferred to the sequencing reactor (FIGURE 9) for mass spectrometric exonuclease sequencing using an immobilized or entrapped exonuclease. In an alternate embodiment, the transcription process is initiated via initiator oligonucleotides with a 5' functionality allowing the subsequent immobilization of the RNA transcripts to a solid support, in this case the mass spectrometric sequencing can be performed within the sequencing reactor using an exonuclease in solution. The step-wise liberated ribonucleotides, or modified ribonucleotides (i.e., ribonucleosides generated by passing through a reactor containing immobilized alkaline phosphatase), are fed to the mass spectrometer for sequence determination.

(ii) Introduction of mass-modified nucleotides for multiplex exonuclease sequencing:

[0051] Since standard mass spectrometry is a serial process, the throughput can be limited. However, in the present invention the throughput can be considerably increased by the introduction of mass-modified nucleotides into the DNA or RNA to be sequenced allowing for a parallel analysis of several nucleic acid sequences simultaneously by mass spectrometry. Low molecular weight nucleic acid components, such as unmodified or mass modified nucleotides/nucleosides, can be analyzed simultaneously by multiplex mass spectrometry.

[0052] Mass-modified nucleotides can be incorporated by way of mass modified nucleoside triphosphates precursors using various methods. For example, one can begin with the insert of the target DNA sequence in a single-stranded cloning vector by having a "primer" and a "stopper" oligonucleotide bound to the complementary vector sequences located at the A and B boundary of the insert DNA respectively (FIGURE 3) and a template directed DNA polymerase, preferentially one lacking the 3'-5' and 5'-3' exonuclease activity such as Sequenase, version 2.0 (US Biochemicals, derived from T7 DNA polymerase), Taq DNA polymerase or AMV reverse transcriptase. In the illustrative embodiment, the unknown DNA sequence has been inserted in a restriction endonuclease site such as Not I. Adjacent to the A boundary another restriction endonuclease site, such as the Asc I site, can be located within the primer binding site such that the partly double-stranded circular DNA can be cleaved at the unique Asc I site and the mass-modified (-) strand ( $t^3$  in FIGURE 3) isolated by standard procedures (i.e., membrane filtration, molecular sieving, PAGE or agarose gel electrophoresis) and, if desired, coupled to a solid support via a splint oligonucleotide restoring the Asc I site in double-stranded form for ligation by T4 DNA ligase (FIGURE 3). After having removed the splint oligonucleotide the immobilized single-stranded DNA fragment with its B' boundary at the 3' end (i.e.,  $Tr^3$ ) is ready for exonuclease mediated mass spectrometric sequencing. In another illustrative embodiment, the same primer can be used even when the vector has no complementary Asc I site. Although the primer will not hybridize with its 5' terminal sequence to the vector as is shown in FIGURE 3, it will nevertheless allow the covalent attachment of the single-stranded mass-modified DNA to the solid support using the same splint oligonucleotide as described above. In yet another embodiment the primer can carry a non-restriction site sequence information at its 5' end, which may or may not be complementary to the opposite vector sequence, but is complementary to a specific splint oligodeoxynucleotide which allows the covalent attachment to the solid support. The latter two procedures do not require cleavage with a restriction endonuclease and separation of the strands.

[0053] The reaction mixture obtained after enzymatic synthesis of the mass-modified (-) strand can be directly joined to the solid support and the circular vector DNA and the stopper oligonucleotide can be removed under denaturing conditions. In yet another embodiment, the generation of a set of ordered deletions of the target DNA sequence information and the incorporation of mass modified nucleotides can be combined by terminating the DNA polymerase reaction at different time intervals (i.e.,  $t^0$ ,  $t^1$ ,  $t^2$ ,  $t^3$ , FIGURE 3) to generate a ladder of mass-modified (-) strands. In case the 3' termini of each time point are too heterogeneous for mass spectrometric exonuclease sequencing a circularization and cloning step as described above can be included.

[0054] As illustrated in FIGURES 14A and 14B, both the (+) and (-) strand can be exonuclease sequenced simultaneously. Incorporation of mass-modified nucleotides in to one of the (+) or (-) strands can be carried out as described above. In the illustrative embodiment, both the (+) and (-) strands are ligated to solid supports and exonucleased simultaneously. The presence of the mass-modified nucleotides in the (-) strand can allow for differentiation of mass spectrometric signals arising from nucleotides released from both strands. Where exonuclease sequencing can proceed essentially between the A and B boundaries in one pass, the sequence of the (-) strand can be inverted and aligned with the complimentary sequence. An advantage to this approach is the identification of ambiguous sequencing data (i.e., base pair mismatches arising from error of sequencing one of the strands). Alternatively, the full sequence can be obtained from partial exonuclease sequencing of both the (+) and (-) strands provided that sequencing proceeds to an overlapping point on each strand. By searching for the complementary overlapping region of each sequence



fragment and aligning the two sequence fragments, the sequence of the remainder of one or both of the strands can be "reconstructed" based on the known sequence of the other. This later example provides a means of sequencing in "one pass" a much larger DNA fragment than would be possible by exonuclease sequencing only one strand.

5 [0055] In using vectors of the phagemid type (e.g. pGEM family, Promega Corp.) both strands of the unknown DNA fragment can be mass-modified by using just the vector which carries the f1 origin of replication in the opposite direction.

10 [0056] As further embodiments of this invention and in analogy to the reactions described above, RNA transcripts of both strands can be obtained utilizing, for example, transcription promoter regions flanking the insertion site, restoring the double-stranded promoter site by complementary oligonucleotides [Methods in Enzymology, Vol. 185, (1990); Uhlenbeck et al., Nucleic Acids Res., (1987), *supra*] and transcribing with appropriate RNA polymerases in the presence of mass-modified ribonucleoside triphosphates. As above, the mass-modified RNA can be directly transferred to the sequencing reactor for mass spectrometric sequencing using an immobilized or entrapped exonuclease. In another embodiment the transcription can be initiated with initiator oligonucleotides [Krupp et al., Gene, (1992), *supra*] carrying a 5' functionality for subsequent attachment of the mass-modified RNAs to a solid support. In the later instance, the immobilized mass-modified RNAs can be contacted in the sequencing reactor (FIGURE 9) with an exonuclease in solution for mass spectrometric sequencing.

15 [0057] The mass-modification of the immobilized strand starting with the unknown DNA insert in a double-stranded vector (FIGURE 4A) can be introduced starting with a situation similar to Tr<sup>0</sup>ds in FIGURE 2. However, a 5' phosphorylated exonuclease III resistant splint oligonucleotide (i.e., 2',3' dideoxy) is ligated to the (-) strand allowing a unilateral digestion of the (+) strand with exonuclease III (FIGURE 4A). The mass-modifications are then introduced by a filling-in reaction using template dependent DNA polymerases such as Sequenase, version 2.0 (US Biochemicals), Taq DNA polymerase or AMV reverse transcriptase and appropriate mass-modified dNTPs. In another embodiment one can start with a situation similar to Tr<sup>0</sup>ss in FIGURE 2 and by using a (-) primer designed to bind outside the A boundary at the 3' end of the (+) strand, synthesize a mass-modified (-) strand employing mass-modified dNTPs and a DNA dependent DNA polymerase as described above. In one embodiment, there can be a short stretch of sequence between the Not I and the Asc I site to allow this primer to hybridize effectively. This approach can also be carried out by generating a mass modified (+) strand starting with Tr<sup>0</sup>ss (FIGURE 4B). The newly synthesized (+) strand can be isolated from the (-) strand solid support, such as by denaturation, and immobilized via the 5' sequence information of the primer and a splint oligonucleotide which is in part complementary to this and to an oligonucleotide sequence already attached to another solid support (FIGURE 4B). After ligation (i.e., with T4 ligase) the splint oligonucleotide is removed and the immobilized mass-modified single-stranded (+) DNA is transferred to the sequencing reactor (FIGURE 9) and contacted with an exonuclease, such as T4 DNA polymerase in solution, for mass spectrometric sequence determination via the released mass-modified nucleotides.

25 [0058] In accordance with this invention, the mass-modifying functionality can be located at different positions within the nucleotide moiety (FIGURE 5 and 6). For instance, the mass-modifying functionality can be located at the heterocyclic base at position C-8 in purine nucleotides (M1) or C-8 and/or C7 (M2) in c7-deazapurine nucleotides and at C-5 in uracil and cytosine and at the C-5 methyl group at thymine residues (M1). Modifications in these positions do not interfere with Watson-Crick specific base-pairing necessary for the enzymatic incorporation into the mass-modified nucleic acids (DNA/RNA) with high accuracy. Modifications introduced at the phosphodiester bond (M4), such as with alpha-thio nucleoside triphosphates, have the advantage that these modifications do not interfere with accurate Watson-Crick base-pairing and additionally allow for the one-step post-synthetic site-specific modification of the complete nucleic acid molecule e.g. via alkylation reactions [K.L. Nakamaye, G. Gish, F. Eckstein and H.-P. Vossberg, Nucleic Acids Res., 16, 9947-59 (1988)]. However, this modification is not applicable where the exonucleolytically released nucleotides are to be treated with immobilized alkaline phosphatase intermediate release and mass spectrometric detection. Mass modification can also occur at the sugar moiety, such as at the position C-2' (M3). Modifications at this position can be introduced with the purpose of modulating the rate of exonuclease activity in order to synchronize the degradation process from time to time. The modification M4 can also serve this purpose. For example, it is known [Burgers and Eckstein, (1979), *supra*] that a phosphodiester bond carrying a monothio function is approximately 100 time less sensitive towards exonucleolytic degradation by exonuclease III.

35 [0059] The tables in FIGURES 7 and 8 depict some examples of mass-modifying functionalities for nucleotides. This list is, however, not meant to be limiting, since numerous other combinations of mass modifying functions and positions within the nucleotide molecule are possible and are deemed part of the invention. The mass modifying functionality can be, for example, a halogen, an azido, or of the type XR. Wherein X is a linking group and R is a mass modifying functionality. The mass modifying functionality can thus be used to introduce defined mass increments into the nucleotide molecule.

45 [0060] Without limiting the scope of the invention, the mass modification, M, can be introduced for X in XR as well as using oligo-/polyethylene glycol derivatives for R. The mass modifying increment in this case is 44, i.e., five different mass modified species could be generated by just changing m from 0 to 4 thus adding mass units of 45 (m=0), 89 (m=1), 133 (m=2), 177 (m=3) and 221 (m=4). The oligo/polyethylene glycols can also be monoalkylated by a lower

alkyl such as methyl, ethyl, propyl, isopropyl, t-butyl and the like. A selection of linking functionalities X are also illustrated in FIGURE 8. Other chemistries can be used in the mass modified compounds, as for example, those described recently in *Oligonucleotides and Analogues, A Practical Approach*, F. Eckstein, editor, IRL Press, Oxford, 1991.

5 [0061] In yet another embodiment, various mass modifying functionalities R, other than oligo/polyethylene glycols, can be selected and attached via appropriate linking chemistries X. A simple mass modification can be achieved by substituting H for halogens like F, Cl, Br and/or I; or pseudohalogens such as SCN, NCS; or by using different alkyl, aryl or aralkyl moieties such as methyl, ethyl, propyl, isopropyl, t-butyl, hexyl, phenyl, substituted phenyl, benzyl; or functional groups such as CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, Si(CH<sub>3</sub>)<sub>3</sub>, Si(CH<sub>3</sub>)<sub>2</sub>(C<sub>2</sub>H<sub>5</sub>), Si(CH<sub>3</sub>)(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>, Si(C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>. Yet another mass modification can be obtained by attaching homo- or heteropeptides through X to the nucleotide. One example useful  
10 in generating mass modified species with a mass increment of 57 is the attachment of oligoglycines, e.g. mass modifications of 74 (r=1, m=0), 131 (r=1, m=2), 188 (r=1, m=3), 245 (r=1, m=4) are achieved. Simple oligoamides also could be used, e.g. mass modifications of 74 (r=1, m=0), 88 (r=2, m=0), 102 (r=3, m=0), 116 (r=4, m=0) etc. are obtainable. For those skilled in the art it will be obvious that there are numerous possibilities, for introducing, in a predetermined manner, many different mass modifying functionalities to the nucleotide.

15 [0062] In yet another embodiment of this invention, the mass modifying functionality can be introduced by a two or multiple step process. In this case the nucleotide is, in a first step, modified by a precursor functionality such as azido, -N<sub>3</sub>, or modified with a functional group in which the R in XR is H thus providing temporary functions e.g. but not limited to -OH, -NH<sub>2</sub>, -NHR, -SH, -NCS, -OCO(CH<sub>2</sub>)<sub>r</sub>COOH (r = 1-20), -NHCO(CH<sub>2</sub>)<sub>r</sub>COOH (r = 1-20), -OSO<sub>2</sub>OH, -OCO(CH<sub>2</sub>)<sub>r</sub> (r = 1-20), -OP(O-Alkyl)N(Alkyl)<sub>2</sub>. These less bulky functionalities result in better substrate properties for enzymatic  
20 DNA or RNA synthesis reactions. The appropriate mass modifying functionality can then be introduced after the generation of the target nucleic acid prior to mass spectrometry and either prior to exonuclease degradation or after release by exonuclease action.

(iii) The exonuclease sequencer:

25 [0063] A schematic outlay of an exonuclease sequencer is shown in FIGURE 9. The central part is the reactor S which has a cooling/heating mantle (2) and a frit or semipermeable membrane (4). Several flasks (R1-R5) can be dedicated to supply reagents such as buffer solutions, enzyme, etc. through a cooling/heating coil T. Beneath the reactor S there is a capillary tube E in which either the exonuclease or the nucleic acids can be immobilized. It is within  
30 the scope of this invention that there are at least two different modes by which the system can be operated. In one mode, the nucleic acids are immobilized on beads or flat membrane disks placed in the reactor S, or alternatively, immobilized on the inner surface of the walls within the capillary E. Exonuclease is added to the reactor in a controlled manner and the reaction mixture circulated through a loop maintained at a carefully controlled temperature. In a second mode, the exonuclease can be immobilized in e.g. a capillary E beneath the reactor S or could be immobilized on  
35 beads or on a membrane or entrapped in a gel or kept in the reactor S by way of a semipermeable membrane. By varying the length and diameter of the capillary and the flow rate through a pumping device P, the contact time of the nucleic acids with the exonuclease can be varied.

[0064] In both process modes, aliquots can be fed either continuously or in pulses to the mass spectrometer either directly or through a reactor AP which contains, for instance, immobilized alkaline phosphatase or other mass-modifying  
40 reagents. In case the liquid volume which is transferred to the mass spectrometer is too large, only a portion can be supplied while the remainder is separated from the flow stream by using a flow splitting device SP. Unused or excess solutions can be disposed of by the waste container W. In case the reaction mixture of the exonuclease digestion is processed via a moving belt the liquid flow can be directed through this module prior to entering the mass spectrometer.

45 (iv) The exonuclease sequencing process:

[0065] Various exonucleases can be used, such as snake venom phosphodiesterase, Bal-31 nuclease, E. coli exonuclease VII, Mung Bean Nuclease, S1 Nuclease, exonuclease and exonuclease III as well as the exonuclease activity of some DNA polymerases such as E. coli DNA polymerase I, the Klenow fragment of DNA polymerase I, T4 or T7  
50 DNA polymerases, Taq DNA polymerase, Deep Vent DNA polymerase, and Vent<sub>1</sub> DNA polymerase. The activity of these exonucleases can be modulated, for instance, by shifting off the optimal pH and/or temperature range or by adding poisoning agents to the reaction mixture. The exonuclease activity can also be modulated by way of functional groups, such as at the C-2' position of the sugar moiety of the nucleotide building block or at the phosphodiester bond (i.e., M3/M4 in FIGURE 5 and 6).

55 [0066] In the instance that unmodified nucleotides are detected, the masses for the phosphate dianion are 329.209 for pdG, 313.210 for pdA, 304.196 for pdT and 289.185 for pdC. In an idealized system the enzymatic digestion would be initiated at all nucleic acid chains at the same time, and the nucleotides would be released in identical time intervals and detected by their individual molecular weights one after the other by the mass spectrometer. FIGURE 10 illustrates

the signals versus time for the sequence 5'...A-T\*-C-C-G-G-A 3'.

[0067] The influence of an activity modulating functionality M3/M4 on appropriately modified thymidine, T\*, is also depicted. Due to the drastically reduced cleavage rate of the phosphodiester bond between dC and dT\* the molecular mass representing the T\* signal appears after a longer time interval f. The significant retardation of the cleavage rate of one type of nucleotide results in better overall synchronization of the enzymatic process. This retardative effect can be varied to a large extent by the bulkiness of the modifying functional group as well as by a possible interaction with the active site of the exonuclease. Additionally, partial overlap of signals can be resolved by computational methods.

(v) Multiplex exonuclease sequencing:

[0068] A significant increase in throughput can be further obtained by employing the principle of multiplex exonuclease sequencing. The principle of this concept is illustrated in FIGURE 11. For multiplex mass spectrometric exonuclease DNA sequencing, the DNA fragments to be processed in parallel can be identified by fragment specific labels introduced by the mass modifying functionality M. The target nucleic acid sequences can be mass-modified by using, for example, unmodified dNTP<sup>0</sup>s or NTP<sup>0</sup>s (Tr<sup>0</sup>), nucleoside triphosphates mass-modified with the same functional group, such as an additional methyl group at the heterocyclic base, using either dNTP<sup>1</sup> or NTP<sup>1</sup> (Tr<sup>1</sup>), mass difference large enough to be discriminated from the nucleotides of Tr<sup>0</sup> or Tr<sup>1</sup>, such as e.g. an ethyl group at the heterocyclic base, by employing either dNTP<sup>2</sup> or NTP<sup>2</sup> etc. Thus i modified DNA fragments can be simultaneously exonuclease sequenced. For example, the i different DNA fragments can be immobilized on different membranes and a stack of such membranes placed into the reactor S (FIGURE 9) for simultaneous exonuclease mass spectrometric sequencing. Since the individual molecular weights of the various mass-modified four nucleotides are known in advance, the mass spectrometrically detected nucleotide masses can be easily assigned to the parent nucleic acid fragments and thus several sequences can be detected simultaneously by the mass spectrometer. Even in the worst case when the same nucleotide, e.g. dT is at the same position in all sequences, processed in parallel the signal can be decoded due to the difference in mass between dT<sup>0</sup>, dT<sup>1</sup>, dT<sup>2</sup>, dT<sup>3</sup>, ..., dT<sup>i</sup>.

[0069] The synchronization of exonuclease action can be improved by incorporating modified nucleotides (modified at C-2' or at the phosphodiester bond) into the otherwise unmodified or mass-modified nucleic acid fragments as set out above. In particular such a mass-modified nucleotide can also be introduced at the 3' end of the single stranded nucleic acid fragment (i.e., C-2' or phosphodiester bond modifications) to achieve a more uniform initiation of the exonuclease reaction.

[0070] In yet another embodiment of this invention, a reduction of overlap of neighboring signals can be achieved by using a moving belt device as schematically shown in FIGURE 12. In a recent publication a moving belt has been described although in a completely unrelated application [M.Moini and F.P. Abramson, *Biological Mass Spectrometry*, 20, 308-12 (1991)]. The effect of the moving belt can be to help spread the appearance of sequentially released nucleotide/nucleoside signals as illustrated in FIGURE 13. The width between consecutive, i.e., neighboring, signals can be increased with the speed of the moving belt.

[0071] Without limiting the scope of the invention FIGURE 12 illustrates a possible configuration of the moving belt module for exonuclease mediated mass spectrometric sequencing. An endless metal ribbon (10) is driven with variable speed using a controllable stepping motor and appropriately positioned pulleys. Spring-loaded pulleys can be used to maintain a sufficiently high tension on the moving belt. The sample is applied to the belt from the reactor module A (FIGURE 9) at a position which is in direct contact with a cooling/heating plate B. In case matrix-assisted laser desorption/ionization mass spectrometry is employed the sample can be mixed with a matrix solution M prior to loading onto the belt. Crystal formation can be observed with a viewing device D (CCD camera and optics). Alternatively the container M can be used to mix the sample with a diluent or other reagent, enzyme, internal standard etc. at a mixing valve or vortex (12). In the instance of relatively small molecules such as the released nucleotides, matrix is not essential for the laser desorption/ionization process to take place. The belt 10 moves the sample under a laser source E (with appropriate optics) for desorption and ionization.

[0072] A heating element C, such as a microwave source, can be placed near the surface of the returning belt, separated from the forward moving belt by an insulating shield I, to clean the surface of the metal ribbon belt 10 of any organic material prior to loading a new sample. Alternatively, a washing station W can be integrated before the heating element C; in this case the function of the heating element C can be completely dry the metal ribbon prior to reloading of sample. Before and after the laser targets the sample, two differential vacuum pumping stages F and G are positioned. An electric field is applied after the second vacuum stage to accelerate the ions into the mass spectrometer. As mass analyzer, a quadrupole can be used, though other mass analyzing configurations are known in the art and are within the scope of the invention. The design of the vacuum interface of the moving belt between the sample application compartment which is at atmospheric pressure, and the mass spectrometer can be important. In one approach, this vacuum seal can be provided by the use of tunnel seals in a two-stage vacuum lock as previously described [Moini et al. (1991), *supra*].



[0073] As described above, an increase of throughput can be obtained by multiplexing. In yet another embodiment of the invention the moving belt device can be used for a second dimension in multiplexing by applying samples from sequencing reactors A (FIGURE 9) simultaneously in different locations onto the moving belt. Desorption and ionization of these multiple samples is achieved by moving the laser beam with adjustable speed and frequency back and forth perpendicular to the direction of the moving belt. Identification and assignment of the nucleotides/nucleosides detected to the various nucleic acid fragments can be achieved by second dimension multiplexing, i.e., by mass-labeling the nucleic acid fragments with for example  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$  and  $-\text{CH}_2(\text{CH}_2)_r\text{CH}_2-$ , and labeling the different reactors, for example, by individual halogen atoms, i.e., F for reactor 1 (thus having the different DNA fragments labeled with  $-\text{CH}_2\text{F}$ ,  $-\text{CH}_2\text{CH}_2\text{F}$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{F}$ ,  $-\text{CH}_2(\text{CH}_2)_r\text{CH}_2\text{F}$ ), Cl for reactor 2 (thus having the different DNA fragments labeled with  $-\text{CH}_2\text{Cl}$ ,  $-\text{CH}_2\text{CH}_2\text{Cl}$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{Cl}$ ,  $-\text{CH}_2(\text{CH}_2)_r\text{CH}_2\text{Cl}$ ), Br for reactor 3 etc. This can increase the throughput dramatically. Two-dimensional multiplexing can be applied in different ways. For example, it can be used to simultaneously sequence the fragments forming one set of overlapping deletions of the same long DNA insert. In another embodiment, several subsets of ordered deletions of different DNA inserts can be analyzed in parallel.

[0074] The enormous advantage of exonuclease mediated mass spectrometric DNA sequencing is that small molecules are analyzed and identified by mass spectrometry. In this mass range, the accuracy of mass spectrometers is routinely very high, i.e., 0.1 mass units are easily detected. This increases the potential for multiplexing as small differences in mass can be detected and resolved. An additional advantage of mass spectrometric sequencing is that the identified masses can be registered automatically by a computer and by adding the time coordinate automatically aligned to sequences. Since the sequences so determined are memorized (i.e., saved to disk or resident in the computer memory) appropriate existing computer programs operating in a multitasking environment can be searching in the "background" (i.e., during continuous generation of new sequence data by the exonuclease mass spectrometric sequencer) for overlaps and generate contiguous sequence information which, via a link to a sequence data bank, can be used in homology searches, etc.

[0075] Another aspect of this invention concerns kits for sequencing nucleic acids by exonuclease mass spectrometry, which include combinations of the above described sequencing reactants. For instance, in one embodiment, the kit comprises reagents for multiplex mass spectrometric sequencing of several different species of nucleic acid. The kit can include an exonuclease for cleaving the nucleic acids unilaterally from a first end to sequentially release individual nucleotides, a set of nucleotides for synthesizing the different species of nucleic acids, at least a portion of the nucleotides being mass-modified such that sequentially released nucleotides of each of the different species of nucleic acids are distinguishable, a polymerase for synthesizing the nucleic acids from complementary templates and the set of nucleotides, and a solid support for immobilizing one of the nucleic acids or the exonuclease. The kit can also include appropriate buffers, as well as instructions for performing multiplex mass spectrometry to concurrently sequence multiple species of nucleic acids. In another embodiment, the sequencing kit can include an exonuclease for cleaving a target nucleic acid unilaterally from a first end to sequentially release individual nucleotides, a set of nucleotides for synthesizing the different species of nucleic acids, at least a portion of the nucleotides being mass-modified to modulate the exonuclease activity, a polymerase for synthesizing the nucleic acid from a complementary template and the set of nucleotides, and a solid support for immobilizing one of the nucleic acids or the exonuclease.

[0076] Another aspect of this invention concerns a "reverse-Sanger" type sequencing method using exonuclease digestion of nucleic acids to produce a ladder of nested digestion fragments detectable by mass spectrometry. For instance, as above, the target nucleic acid can be immobilized to a solid support to provide unilateral degradation of the chain by exonuclease action. Incorporating into the target nucleic acid a limited number of mass-modified nucleotides which inhibit the exonuclease activity (i.e., protect an individual nucleic acid chain from further degradation) can result in a ladder of nested exonuclease fragments. See Labeit et al. (1988) DNA 5:173; Eckstein et al. (1988) Nucleic Acid Res. 16:9947; and PCT Application No. GB86/00349 (WO/86 07612). The nested exonuclease fragments can then be released from the solid support (i.e., via a cleavable linkage) and the molecular weight values for each species of the nested fragments determined by mass spectrometry. From the molecular weight values determined, the sequence of the nucleic acid can be generated. It is clear that many variations of this reaction are possible and that it is amenable to multiplexing. For example, the target nucleic acid need not be bound to a solid support, rather any protecting group can be used to ensure unilateral exonuclease degradation. Where mass-modified nucleotides are used which have large enough molecular weight differences to be differentiated between by mass spectrometry (i.e., the termination of a chain with a particular mass-modified nucleotide is discernable from all other terminations), the exonuclease sequencing can be carried out to create only one set of nested fragments. Alternatively, individual types of exonuclease-inhibiting nucleotides can be incorporated in separate reactions to create sets of nested fragments. For instance, four sets of nested fragments can be separately generated wherein one set terminates with mass-modified A's, one set terminates in mass-modified G's, etc. and the total sequence is determined by aligning the collection of nested exonuclease fragments.

## EXAMPLE 1

Immobilization of nucleic acids to solid supports via disulfide bonds.

- 5 [0077] As a solid support, SEQUELON membranes (Millipore Corp., Bedford, MA) with phenyl isothiocyanate groups is used as a starting material. The membrane disks, with a diameter of 8 mm, are wetted with a solution of N-methylmorpholine/water/2-propanol (NMM solution) (2/49/49; v/v/v), the excess liquid removed with filterpaper and placed on a piece of plastic film or aluminium foil located on a heating block set to 55°C. A solution of 1 mM 2-mercaptoethylamine (cysteamine) or 2,2'-dithio-bis(ethylamine) (cystamine) or S-(2-thiopyridyl)-2-thio-ethylamine (10 µl, 10 nmol) in NMM is added per disk and heated at 55°C. After 15 min 10 µl of NMM solution are added per disk and heated for another 5 min. Excess of isothiocyanate groups may be removed by treatment with 10 µl of a 10 mM solution of glycine in NMM solution. In case of cystamine the disks are treated with 10 µl of a solution of 1M aqueous dithiothreitol (DTT)/2-propanol (1:1, v/v) for 15 min at room temperature. Then the disks are thoroughly washed in a filtration manifold with 5 aliquots of 1 ml each of the NMM solution, then with 5 aliquots of 1 ml acetonitrile/water (1/1; v/v) and subsequently dried. If not used immediately the disks are stored with free thiol groups in a solution of 1M aqueous dithiothreitol/2-propanol (1:1; v/v) and, before use, DTT is removed by three washings with 1ml each of the NMM solution. Single-stranded nucleic acid fragments with 5'-SH functionality can be prepared by various methods [e.g. B.C.F Chu et al., Nucl. Acids Res., 14, 5591-5603 (1986), Sproat et al., Nucleic Acids Res., 15, 4837-48 (1987) and Oligonucleotides and Analogues. A Practical Approach (F. Eckstein editor), IRL Press Oxford, 1991]. The single-stranded nucleic acid fragments with free 5'-thiol group are now coupled to the thiolated membrane supports under mild oxidizing conditions. In general it is sufficient to add the 5'-thiolated nucleic acid fragments dissolved in 10 µl 10 mM deaerated triethylammonium acetate buffer (TEAA) pH 7.2 to the thiolated membrane supports; coupling is achieved by drying the samples onto the membrane disks with a cold fan. This process can be repeated by wetting the membrane with 10 µl of 10 mM TEAA buffer pH 7.2 and drying as before. When using the 2-thiopyridyl derivatized compounds anchoring can be monitored by the release of pyridine-2-thione spectrophotometrically at 343 nm.
- 15 [0078] In another variation of this approach the single-stranded nucleic acid is functionalized with an amino group at the 5'-end by standard procedures. The primary amino group is reacted with 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) and subsequently coupled to the thiolated supports and monitored by the release of pyridine-2-thione as described above. After denaturation of any remaining protein and ethanol precipitation of the functionalized nucleic acid, the pellet is dissolved in 10 µl 10 mM TEAA buffer pH 7.2 and 10 µl of a 2 mM solution of SPDP in 10 mM TEAA are added. The reaction mixture is vortexed and incubated for 30 min at 25°C; excess SPDP is then removed by three extractions (vortexing, centrifugation) with 50 µl each of ethanol and the resulting pellets dissolved in 10 µl 10 mM TEAA buffer pH 7.2 and coupled to the thiolated supports (see above).
- 20 [0079] The immobilized nucleic acids can be released by three successive treatments with 10 µl each of 10 mM 2-mercaptoethanol in 10 mM TEAA buffer pH 7.2.
- 25
- 30
- 35

## EXAMPLE 2

Immobilization of nucleic acids on solid support via a levulinyl group.

- 40 [0080] 5-Aminolevulinic acid is protected at the primary amino group with the Fmoc group using 9-fluorenylmethyl N-succinimidyl carbonate and then transformed into the N-hydroxysuccinimide ester (NHS ester) using N-hydroxysuccinimide and dicyclohexyl carbodiimide under standard conditions. Nucleic acids which are functionalized with primary amino acid at the 5' end are EtOH precipitated and resuspended in 10 µl of 10 mM TEAA buffer pH 7.2. 10 µl of a 2 mM solution of the Fmoc-5-aminolevulinyl-NHS ester in 10 mM TEAA buffer is added, vortexed and incubated at 25°C for 30 min. The excess of reagents can be removed by ethanol precipitation and centrifugation. The Fmoc group is cleaved off by resuspending the pellets in 10 µl of a solution of 20% piperidine in N,N-dimethylformamide/water (1:1, v/v). After 15 min at 25°C piperidine is thoroughly removed by three precipitations/centrifugations with 100 µl each of ethanol, the pellets resuspended in 10 µl of a solution of N-methylmorpholine, propanol-2 and water (2/10/88; v/v/v) and coupled to the solid support carrying an isothiocyanate group. In case of the DITC-Sequelon membrane (Millipore Corp., Bedford, MA) the membranes are prepared as described in EXAMPLE 1 and coupling is achieved on a heating block at 55°C as described above. The procedure can be applied to other solid supports with isothiocyanate groups in a similar manner.
- 45
- 50
- 55 [0081] The immobilized nucleic acids can be released from the solid support by three successive treatments with 10 µl of 100 mM hydrazinium acetate buffer pH 6.5.

## EXAMPLE 3

Immobilization of nucleic acids on solid supports via a trypsin sensitive linkage.

- 5 [0082] Sequelon DITC membrane disks of 8 mm diameter (Millipore Corp. Bedford, MA) are wetted with 10 ul of NMM solution (N-methylmorpholine/propanol-2/water; 2/49/49;v/v/v) and a linker arm introduced by reaction with 10 ul of a 10 mM solution of 1,6-diaminohexane in NMM. The excess of the diamine is removed by three washing steps with 100 ul of NMM solution. Using standard peptide synthesis protocols two L-lysine residues are attached by two successive condensations with N-Fmoc-N-tBoc-L-lysine pentafluorophenylester, the terminal Fmoc group is removed with piperidine in NMM and the free  $\alpha$ -amino group coupled to 1,4-phenylene diisothiocyanate (DITC). Excess DITC is removed by three washing steps with 100 ul propanol-2 each and the N-tBoc groups removed with trifluoroacetic acid according to standard peptide synthesis procedures. The nucleic acids are prepared from as above from a primary amino group at the 5'-terminus. The ethanol precipitated pellets are resuspended in 10 ul of a solution of N-methylmorpholine, propanol-2 and water (2/10/88; v/v/v) and transferred to the Lys-Lys-DITC membrane disks and coupled on a heating block set at 55°C. After drying 10 ul of NMM solution is added and the drying process repeated.
- 15 [0083] The immobilized nucleic acids can be cleaved from the solid support by treatment with trypsin.

## EXAMPLE 4

- 20 Immobilization of nucleic acids on solid supports via pyrophosphate linkage.

- [0084] The DITC Sequelon membrane (disks of 8 mm diameter) are prepared as described in EXAMPLE 3 and 10 ul of a 10 mM solution of 3-aminopyridine adenine dinucleotide (APAD) (Sigma) in NMM solution added. The excess of APAD is removed by a 10 ul wash of NMM solution and the disks are treated with 10 ul of 10 mM sodium periodate in NMM solution (15 min, 25°C). Excess of periodate is removed and the having a primary amino group at the 5'-end are dissolved in 10 ul of a solution of N-methylmorpholine/propanol-2/water (2/10/88; v/v/v) and coupled to the 2',3'-dialdehyde functions of the immobilized NAD analog.
- 25 [0085] The immobilized nucleic acids can be released from the solid support by treatment with either NADase or pyrophosphatase in 10 mM TEAA buffer at pH 7.2 at 37°C for 15 min.

30

## EXAMPLE 5

Synthesis of pyrimidine nucleotides mass modified at C-5 of the heterocyclic base with glycine residues.

- 35 [0086] Starting material is 5-(3-aminopropynyl-1)-3',5'-di-p-tolyldeoxyuridine prepared and 3',5'-de-O-acylated according to literature procedures [Haralambidis et al., Nucleic Acids Res., 15, 4857-76 (1987)]. 0.281 g (1.0 mmole) 5-(3-aminopropynyl-1)-2'-deoxyuridine are reacted with 0.927 g (2.0 mmole) N-Fmoc-glycine pentafluorophenylester in 5 ml absolute N,N-dimethylformamide in the presence of 0.129 g (1 mmole; 174 ul) N,N-diisopropylethylamine for 60 min at room temperature. Solvents are removed by rotary evaporation and the product purified by silica gel chromatography (Kieselgel 60, Merck; column: 2.5x 50 cm, elution with chloroform/methanol mixtures). Yield 0.44 g (0.78 mmole, 78 %). In order to add another glycine residue the Fmoc group is removed with a 20 min treatment with 20 % solution of piperidine in DMF, evaporated in vacuo and the remaining solid material extracted three times with 20 ml ethylacetate; after having removed the remaining ethylacetate N-Fmoc-glycine pentafluorophenylester is being coupled as described above. This glycine modified thymidine analogue building block for chemical DNA synthesis can be used
- 40 to substitute for thymidine or uridine nucleotides in the target nucleic acid.
- 45

## EXAMPLE 6

Synthesis of pyrimidine nucleotides mass modified at C-5 of the heterocyclic base with  $\beta$ -alanine residues.

50

- [0087] Starting material is the same as in EXAMPLE 5. 0.281 g (1.0 mmole) 5-(3-Aminopropynyl-1)-2'-deoxyuridine is reacted with N-Fmoc- $\beta$ -alanine pentafluorophenylester (0.955 g, 2.0 mmole) in 5 ml N,N-dimethylformamide (DMF) in the presence of 0.129 g (174 ul; 1.0 mmole) N,N-diisopropylethylamine for 60 min at room temperature. Solvents are removed and the product purified by silica gel chromatography as described in EXAMPLE 6. Yield: 0.425 g (0.74 mmole, 74 %). Another  $\beta$ -alanine moiety could be added in exactly the same way after removal of the Fmoc group. This building block can be substitute for any of the thymidine or uridine residues in the target nucleic acid.
- 55



## EXAMPLE 7

Synthesis of a pyrimidine nucleotide mass modified at C-5 of the heterocyclic base with ethylene glycol monomethyl ether.

5 [0088] As nucleosidic component 5-(3-aminopropynyl-1)-2'-deoxyuridine is used in this example (see EXAMPLE 5 and 6). The mass-modifying functionality is obtained as follows: 7.61 g (100.0 mmole) freshly distilled ethylene glycol monomethyl ether dissolved in 50 ml absolute pyridine is reacted with 10.01 g (100.0 mmole) recrystallized succinic anhydride in the presence of 1.22 g (10.0 mmole) 4-N,N-dimethylaminopyridine overnight at room temperature. The reaction is terminated by the addition of water (5.0 ml), the reaction mixture evaporated in vacuo, co-evaporated twice with dry toluene (20 ml each) and the residue redissolved in 100 ml dichloromethane. The solution is extracted successively, twice with 10 % aqueous citric acid (2 x 20 ml) and once with water (20 ml) and the organic phase dried over anhydrous sodium sulfate. The organic phase is evaporated in vacuo, the residue redissolved in 50 ml dichloromethane and precipitated into 500 ml pentane and the precipitate dried in vacuo. Yield: 13.12 g (74.0 mmole; 74 %). 8.86 g (50.0 mmole) of succinylated ethylene glycol monomethyl ether is dissolved in 100 ml dioxane containing 5 % dry pyridine (5 ml) and 6.96 g (50.0 mmole) 4-nitrophenol and 10.32 g (50.0 mmole) dicyclohexylcarbodiimide is added and the reaction run at room temperature for 4 hours. Dicyclohexylurea is removed by filtration, the filtrate evaporated in vacuo and the residue redissolved in 50 ml anhydrous DMF. 12.5 ml (about 12.5 mmole 4-nitrophenylester) of this solution is used to dissolve 2.81 g (10.0 mmole) 5-(3-aminopropynyl-1)-2'-deoxyuridine. The reaction is performed in the presence of 1.01 g (10.0 mmole; 1.4 ml) triethylamine at room temperature overnight. The reaction mixture is evaporated in vacuo, co-evaporated with toluene, redissolved in dichloromethane and chromatographed on silicagel (Si60, Merck; column 4x50 cm) with dichloromethane/methanol mixtures. The fractions containing the desired compound are collected, evaporated, redissolved in 25 ml dichloromethane and precipitated into 250 ml pentane.

## 25 EXAMPLE 8

Synthesis of pyrimidine nucleotides mass-modified at C-5 of the heterocyclic base with diethylene glycol monomethyl ether.

30 [0089] Nucleosidic starting material is as in previous examples, 5-(3-aminopropynyl-1)-2'-deoxyuridine. The mass-modifying functionality is obtained similar to EXAMPLE 7. 12.02 g (100.0 mmole) freshly distilled diethylene glycol monomethyl ether dissolved in 50 ml absolute pyridine is reacted with 10.01 g (100.0 mmole) recrystallized succinic anhydride in the presence of 1.22 g (10.0 mmole) 4-N,N-dimethylaminopyridine (DMAP) overnight at room temperature. The work-up is as described in EXAMPLE 7. Yield: 18.35 g (82.3 mmole, 82.3 %). 11.06 g (50.0 mmole) of succinylated diethylene glycol monomethyl ether is transformed into the 4-nitrophenylester and subsequently 12.5 mmole reacted with 2.81 g (10.0 mmole) of 5-(3-aminopropynyl-1)-2'-deoxyuridine as described in EXAMPLE 7. Yield after silica gel column chromatography and precipitation into pentane: 3.34 g (6.9 mmole, 69 %).

## 40 EXAMPLE 9

Synthesis of deoxyadenosine mass-modified at C-8 of the heterocyclic base with glycine.

45 [0090] Starting material is N6-benzoyl-8-bromo-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine prepared according to literature [Singh et al., Nucleic Acids Res. 18, 3339-45 (1990)]. 632.5 mg (1.0 mmole) of this 8-bromo-deoxyadenosine derivative is suspended in 5 ml absolute ethanol and reacted with 251.2 mg (2.0 mmole) glycine methyl ester (hydrochloride) in the presence of 241.4 mg (2.1 mmole; 366  $\mu$ l) N,N-diisopropylethylamine and refluxed until the starting nucleosidic material has disappeared (4-6 hours) as checked by thin layer chromatography (TLC). The solvent is evaporated and the residue purified by silica gel chromatography (column 2.5x50 cm) using solvent mixtures of chloroform/methanol containing 0.1 % pyridine. The product fractions are combined, the solvent evaporated, dissolved in 5 ml dichloromethane and precipitated into 100 ml pentane. Yield: 487 mg (0.76 mmole, 76 %).

## EXAMPLE 10

Synthesis of deoxyadenosine mass-modified at C-8 of the heterocyclic base with glycylglycine.

55 [0091] This derivative is prepared in analogy to the glycine derivative of EXAMPLE 9. 632.5 mg (1.0 mmole) N6-Benzoyl-8-bromo-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine is suspended in 5 ml absolute ethanol and reacted with 324.3 mg (2.0 mmole) glycyl-glycine methyl ester in the presence of 241.4 mg (2.1 mmole, 366  $\mu$ l) N,N-diisopropyl-

ethylamine. The mixture is refluxed and completeness of the reaction checked by TLC. Work-up and purification is similar as described in EXAMPLE 9. Yield after silica gel column chromatography and precipitation into pentane: 464 mg (0.65 mmole, 65 %).

#### 5 EXAMPLE 11

Synthesis of deoxythymidine mass-modified at the C-2' of the sugar moiety with ethylene glycol monomethyl ether residues.

10 [0092] Starting material is 5'-O-(4,4-dimethoxytrityl)-2'-amino-2'-deoxythymidine synthesized according to published procedures [e.g. Verheyden et al., J. Org. Chem., 36, 250-254 (1971); Sasaki et al., J. Org. Chem., 41, 3138-3143 (1976); Imazawa et al., J. Org. Chem., 44, 2039-2041 (1979); Hobbs et al., J. Org. Chem., 42, 714-719 (1976); Ikehara et al., Chem. Pharm. Bull. Japan, 26, 240-244 (1978); see also PCT Application WO 88/00201]. 5'-O-(4,4-Dimethoxytrityl)-2'-amino-2'-deoxythymidine (559.62 mg; 1.0 mmole) is reacted with 2.0 mmole of the 4-nitrophenyl ester of succinylated ethylene glycol monomethyl ether (see EXAMPLE 7) in 10 ml dry DMF in the presence of 1.0 mmole (140  
15 ul) triethylamine for 18 hours at room temperature. The reaction mixture is evaporated in vacuo, co-evaporated with toluene, redissolved in dichloromethane and purified by silica gel chromatography (Si60, Merck, column: 2.5x50 cm; eluent: chloroform/methanol mixtures containing 0.1 % triethylamine). The product containing fractions are combined, evaporated and precipitated into pentane. Yield: 524 mg (0.73 mmol; 73 %).

20 [0093] In an analogous way, employing the 4-nitrophenyl ester of succinylated diethylene glycol monomethyl ether (see EXAMPLE 8) and triethylene glycol monomethyl ether the corresponding mass modified deoxythymidine is prepared. The mass difference between the ethylene, diethylene and triethylene glycol derivatives is 44.05, 88.1 and 132.15 dalton respectively.

#### 25 EXAMPLE 12

Synthesis of deoxyuridine-5'-triphosphate mass-modified at C-5 of the heterocyclic base with glycine, glycyglycine and  $\beta$ -alanine residues.

30 [0094] 0.281 g (1.0 mmole) 5-(3-Aminopropynyl-1)-2'-deoxyuridine (see EXAMPLE 5) is reacted with either 0.927 g (2.0 mmole) N-Fmoc-glycine pentafluorophenylester or 0.955g (2.0 mmole) N-Fmoc- $\beta$ -alanine pentafluorophenyl ester in 5 ml dry DMF in the presence of 0.129 g N,N-diisopropylethylamine (174 ul, 1.0 mmole) overnight at room temperature. Solvents are removed by evaporation in vacuo and the condensation products purified by flash chromatography on silica gel [Still et al., J. Org. Chem., 43, 2923-2925 (1978)]. Yields: 476 mg (0.85 mmole; 85 %) for the glycine and  
35 436 mg (0.76 mmole; 76 %) for the -alanine derivative. For the synthesis of the glycyglycine derivative the Fmoc group of 1.0 mmole Fmoc-glycine-deoxyuridine derivative is removed by one-hour treatment with 20 % piperidine in DMF at room temperature. Solvents are removed by evaporation in vacuo, the residue is co-evaporated twice with toluene and condensed with 0.927 g (2.0 mmole) N-Fmoc-glycine pentafluorophenyl ester and purified following standard protocol. Yield: 445 mg (0.72 mmole; 72 %). The glycyglycyl-, glycyglycylglycyl- and  $\beta$ -alanyl-2'-deoxyuridine derivatives N-protected with the Fmoc group are now transformed to the 3'-O-acetyl derivatives by tritylation with 4,4-dimethoxytrityl chloride in pyridine and acetylation with acetic anhydride in pyridine in a one-pot reaction and subsequently detritylated by one-hour treatment with 80 % aqueous acetic acid according to standard procedures. Solvents are removed, the residues dissolved in 100 ml chloroform and extracted twice with 50 ml 10 % sodium bicarbonate and once with 50 ml  
40 water, dried with sodium sulfate, the solvent evaporated and the residues purified by flash chromatography on silica gel. Yields: 361 mg (0.60 mmole; 71 %) for the glycyglycyl-, 351 mg (0.57 mmole; 75 %) for the -alanyl- and 323 mg (0.49 mmole; 68 %) for the glycyglycylglycyl-3'-O'-acetyl-2'-deoxyuridine derivatives respectively. Phosphorylation at the 5'-OH with POCl<sub>3</sub>, transformation into the 5'-triphosphate by in-situ reaction with tetra(tri-n-butylammonium) pyrophosphate in DMF, 3'-de-O-acetylation and cleavage of the Fmoc group and final purification by anion-exchange chromatography on DEAE-Sephadex is performed. Yields according to UV-absorbance of the uracil moiety: 5-(3-(N-glycyl)-amidopropynyl-1)-2'-deoxyuridine-5'-triphosphate 0.41 mmole (84 %), 5-(3-(N--alanyl)-amidopropynyl-1)-2'-deoxyuridine-5'-triphosphate 0.43 mmole (75 %) and 5-(3-(N-glycylglycyl)-amidopropynyl-1)-2'-deoxyuridine-5'-triphosphate 0.38 mmole (78 %).

#### EXAMPLE 13

55

Synthesis of 8-glycyl- and 8-glycylglycyl-2'-deoxyadenosine-5'-triphosphate.

[0095] 727 mg (1.0 mmole) of N6-(4-tert.butylphenoxyacetyl)-8-glycyl-5'-(4,4-dimethoxytrityl)-2'-deoxyadenosine

or 800 mg (1.0 mmole) N6-(4-tert.butylphenoxyacetyl)-8-glycyl-glycyl-5'-(4,4-dimethoxytrityl)-2'-deoxyadenosine prepared according to EXAMPLES 9 and 10 and literature [Koster et al., Tetrahedron, 37 : 382 (1981)] are acetylated with acetic anhydride in pyridine at the 3'-OH, detritylated at the 5'-position with 80 % acetic acid in a one-pot reaction and transformed into the 5'-triphosphates via phosphorylation with POCl<sub>3</sub> and reaction in-situ with tetra(tri-n-butylammonium) pyrophosphate. Deprotection of the N6-tert-butylphenoxyacetyl, the 3'-O-acetyl and the O-methyl group at the glycine residues is achieved with concentrated aqueous ammonia for three hours at room temperature. Ammonia is removed by lyophilization and the residue washed with dichloromethane, solvent removed by evaporation in vacuo and the remaining solid material purified by anion-exchange chromatography on DEAE-Sephadex using a linear gradient of triethylammonium bicarbonate from 0.1 to 1.0 M. The nucleoside triphosphate containing fractions (checked by TLC on polyethylenimine cellulose plates) are combined and lyophilized. Yield of the 8-glycyl-2'-deoxyadenosine-5'-triphosphate (determined by the UV-absorbance of the adenine moiety) is 57 % (0.57 mmole); the yield for the 8-glycyl-glycyl-2'-deoxyadenosine-5'-triphosphate is 51 % (0.51 mmole).

## SEQUENCE LISTING

[0096]

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: KOSTER, HUBERT  
(B) STREET: 1640 MONUMENT STREET  
(C) CITY: CONCORD  
(D) STATE: MASSACHUSETTS  
(E) COUNTRY: USA  
(F) POSTAL CODE (ZIP): 01742  
(G) TELEPHONE: (508) 369-9790

## (ii) TITLE OF INVENTION: DNA SEQUENCING BY MASS SPECTROMETRY

## (iii) NUMBER OF SEQUENCES: 6

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: ASCII text

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/034,738  
(B) FILING DATE: 19 March 1993  
(C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/034,738  
(B) FILING DATE: 19-MAR-1993  
(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: DeConti, Giulio A.  
(B) REGISTRATION NUMBER: 31,503  
(C) REFERENCE/DOCKET NUMBER: HKI-005PC



(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (617) 227-7400  
(B) TELEFAX: (617) 227-5941

5

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 10 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: YES

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCCTTAGCTA

10

25

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

30

- (A) LENGTH: 14 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: YES

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCGGCCGCAG GTCA

14

45

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 14 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	AATTCAGCGG CCGC	14
5	(2) INFORMATION FOR SEQ ID NO:4:	
	(i) SEQUENCE CHARACTERISTICS:	
10	(A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
15	(ii) MOLECULE TYPE: other nucleic acid	
	(iii) HYPOTHETICAL: YES	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:	
20	GGCCGCAGGT CA	12
	(2) INFORMATION FOR SEQ ID NO:5:	
25	(i) SEQUENCE CHARACTERISTICS:	
30	(A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: cDNA	
35	(iii) HYPOTHETICAL: YES	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:	
40	GGCCGCTGAA TT	12
	(2) INFORMATION FOR SEQ ID NO:6:	
	(i) SEQUENCE CHARACTERISTICS:	
45	(A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
50	(ii) MOLECULE TYPE: other nucleic acid	
	(iii) HYPOTHETICAL: YES	
55	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:	
	GCTAACTTGC	10

Claims

Claims for the following Contracting States : CH, DE, FR, GB, IT, LI, SE

- 5 1. A method of determining a sequence of a nucleic acid, comprising
  - (i) isolating the nucleic acid to be sequenced;
  - (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to sequentially release individual nucleotides;
  - 10 (iii) measuring the mass of each of the sequentially released nucleotides by mass spectrometry to indicate the identity thereof; and
  - (iv) determining the sequence of the nucleic acid from the identified nucleotides.
- 15 2. The method according to claim 1, wherein the nucleic acid is a 2'-deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA).
3. The method according to claim 1 or claim 2 wherein the exonuclease activity is selected from a group consisting of snake venom phosphodiesterase, spleen phosphodiesterase, Bal-31 nuclease, *E. coli* exonuclease I, *E. coli* exonuclease VII, Mung Bean Nuclease, S1 Nuclease, an exonuclease activity of *E. coli* DNA polymerase I, an exonuclease activity of a Klenow fragment of DNA polymerase I, an exonuclease activity of T4 DNA polymerase, an exonuclease activity of T7 DNA polymerase, an exonuclease activity of Taq DNA polymerase, an exonuclease activity of Deep Vent® DNA polymerase, exonuclease III, exonuclease and an exonuclease activity of Vent® DNA polymerase.
- 20 4. The method according to any one of claims 1, 2 and 3 wherein the exonuclease activity is immobilized by covalent attachment to a solid support, entrapment within a gel matrix or contained in a reactor with a semipermeable membrane.
5. The method according to claim 4 wherein the solid support for the exonuclease activity is (a) a capillary and the exonuclease activity is covalently attached to the inner wall of the capillary; or (b) selected from the group consisting of glass beads, cellulose beads, polystyrene beads, Sephadex® beads, Sepharose® beads, polyacrylamide beads and agarose beads; or (c) a flat membrane.
- 30 6. The method according to any one of claims 1, 2 and 3 wherein the isolated nucleic acid is immobilized by covalent attachment to a solid support and the exonuclease activity is in a solution contacted with the immobilized nucleic acid.
7. The method of claim 6 wherein the solid support for the nucleic acid is (a) a capillary and the nucleic acid is covalently attached to the inner wall of the capillary; or (b) selected from the group consisting of glass beads, cellulose beads, polystyrene beads, Sephadex® beads, Sepharose® beads, polyacrylamide beads and agarose beads; or (c) a flat membrane.
- 40 8. The method according to any one of the preceding claims wherein the nucleic acid comprises mass-modified nucleotides.
9. The method according to any one of claims 1 to 8 wherein said sequentially released nucleotides are mass-modified subsequent to exonuclease release and prior to mass spectrometric identification.
- 50 10. The method according to claim 9 wherein sequential release is effected by contact with alkaline phosphatase.
11. The method according to claim 8 wherein the mass-modified nucleotides modulate the rate of exonuclease activity.
12. The method according to any one of the preceding claims wherein i different species of nucleic acids are concurrently sequenced by multiplex mass spectrometric sequencing and the sequential released nucleotides from each species of the i nucleic acids can be distinguished by mass spectrometry from the sequentially released nucleotides from the remaining i-1 nucleic acids based on a difference in mass due to mass-modification of at least a portion of the sequentially released nucleotides.
- 55



13. The method according to claim 12 wherein the mass-modified nucleotides modulate the rate of exonuclease activity.
- 5 14. The method according to claim 12 wherein the mass-modified nucleotide comprises a mass-modifying functionality (M) attached to the sequentially released nucleotide.
15. The method according to claim 12, wherein
  - 10 (a) at least one of the mass-modified nucleotides is modified with a mass modifying functionality (M) attached to a 5' phosphate; or (b) at least one of the mass-modified nucleotides is modified with a mass-modifying functionality (M) attached to a C-2' position of a sugar moiety; or (c) at least one of the mass-modified nucleotides is modified with a mass modifying functionality (M) attached to a heterocyclic base.
- 15 16. The method of claim 15 wherein the mass-modified nucleotide comprises a modified heterocyclic base selected from the group consisting of a cytosine moiety modified at C-5, an uracil moiety modified at C-5, a thymine moiety modified at the C-5 methyl group, an adenine moiety modified at C-8, a c7-deazaadenine moiety modified at C-8, a c7-deazaadenine moiety modified at C-7, a guanine moiety modified at C-8, a c7-deazaguanine moiety modified at C-8, a c7-deazaguanine moiety modified at C-7, a hypoxanthine moiety modified at C-8, a c7-deazahypoxanthine moiety modified at C-8 and a c7-deazahypoxanthine moiety modified at C-7.
- 20 17. The method according to claim 8 wherein the mass-modified nucleic acid is prepared from a single-stranded template polynucleotide complementary to the nucleic acid sequence by synthesizing the nucleic acid using mass-modified nucleotides.
- 25 18. The method of claim 17 wherein (a) the mass-modified nucleic acid is synthesized using a DNA polymerase and mass-modified deoxyribonucleoside triphosphates (dNTPs); or (b) the mass-modified nucleic acid is synthesized using a RNA polymerase and mass-modified ribonucleoside triphosphates (NTPs).
- 30 19. The method according to claim 17 wherein (a) the mass-modified nucleic acid is synthesized using a primer having a sequence which allows the nucleic acid to be anchored to the solid support; or (b) synthesis of the nucleic acid is initiated in the presence of an initiator oligonucleotide having a 5'-functionality allowing the nucleic acid to be immobilized on the solid support.
- 35 20. The method according to claim 6 wherein the nucleic acid further comprises a linking group (L) for covalently attaching the nucleic acid to the solid support.
- 40 21. The method of claim 20 wherein the solid support further comprises a splint oligonucleotide and the linking group (L) comprises a nucleotide sequence able to anneal to the splint oligonucleotide and be covalently attached to the solid support by action of a ligase activity.
- 45 22. A kit for sequencing nucleic acids by exonuclease-mediated mass spectrometry, comprising
  - (i) an exonuclease activity for cleaving the nucleic acids unilaterally from a first end to sequentially release individual nucleotides;
  - (ii) a set of nucleotides for synthesizing the nucleic acid;
  - (iii) a polymerase for synthesizing the nucleic acid from a complementary template and the set of nucleotides;
  - and
  - (iv) a solid support for immobilizing the nucleic acid or the exonuclease,
- 50 wherein at least a portion of the set of nucleotides is mass modified to modulate cleavage activity of the exonuclease.
23. The kit according to claim 22 wherein the nucleic acids further comprise at least two different species of nucleic acid.
- 55 24. The kit according to claims 22 or 23 wherein the nucleic acids are 2' deoxyribonucleic acids (DNA) or ribonucleic acids (RNA).
25. The kit according to claim 22, 23 or 24 wherein the exonuclease activity is selected from a group consisting of

snake venom phosphodiesterase, spleen phosphodiesterase, Bal-31 nuclease, *E. coli* exonuclease I, *E. coli* exonuclease VII, Mung Bean Nuclease, S1 nuclease, an exonuclease activity of *E. coli* DNA polymerase I, an exonuclease activity of a Klenow fragment of DNA polymerase I, an exonuclease activity of T4 DNA polymerase, an exonuclease activity of T7 DNA polymerase, an exonuclease activity of Taq DNA polymerase, an exonuclease activity of Deep Vent® DNA polymerase, exonuclease, exonuclease III and an exonuclease activity of Vent® DNA polymerase.

26. The kit according to any one of claims 22 to 25 wherein the solid support is selected from the group consisting of a capillary, a flat membrane, glass beads, cellulose beads, polystyrene beads, Sephadex® beads, Sepharose® beads, polyacrylamide beads and agarose beads.

27. The kit according to any one of claims 22 to 26 wherein the solid support is functionalized to facilitate covalent attachment of the nucleic acids.

28. The kit according to any one of claims 22 to 27 wherein the exonuclease activity is immobilized by covalent attachment to the solid support.

29. The kit according to any one of claims 22-28 wherein the mass-modified nucleotide comprise a mass-modified functionality (M) attached to a nucleotide moiety.

30. The kit according to claim 29 wherein the mass-modifying functionality (M) is attached to a nucleotide moiety at a position selected from a group consisting of a 5' phosphate, a C-2' position of a sugar moiety and a heterocyclic base.

31. The kit according to any one of claims 22 to 30 further comprising an instruction manual providing the exonuclease sequencing protocol.

32. A kit according to any one of claims 22 to 31 wherein at least a portion of the set of nucleotides is mass-modified such that sequentially released nucleotides of each of the different species are distinguishable.

33. A method of determining a sequence of a nucleic acid, comprising

- (i) isolating the nucleic acid to be sequenced;
- (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to produce a set of nucleic acid fragments;
- (iii) identifying the molecular weight value of each one of the set of nucleic acid fragments by mass spectrometry; and
- (iv) determining the sequence of the nucleic acid from the molecular weight values of the set of nucleic acid fragments; wherein the isolated nucleic acid is immobilized by covalent attachment to a solid support.

34. The method according to claim 33 wherein the nucleic acid is a 2'-deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA).

35. The method according to claim 33 or claim 34 wherein the exonuclease activity is selected from the group consisting of snake venom phosphodiesterase, spleen phosphodiesterase, Bal-31 nuclease, *E. coli* exonuclease I, *E. coli* exonuclease VII, Mung Bean Nuclease, S1 Nuclease, an exonuclease activity of *E. coli* DNA polymerase I, an exonuclease activity of the Klenow fragment of DNA polymerase I, an exonuclease activity of T4 DNA polymerase, an exonuclease activity of T7 DNA polymerase, an exonuclease activity of Taq DNA polymerase, an exonuclease activity of Deep Vent® DNA polymerase, exonuclease III, exonuclease and an exonuclease activity of Vent® DNA polymerase.

36. The method of any one of claims 33 to 35 wherein the nucleic acid comprises mass-modified nucleotides.

37. A method according to any of claims 1 to 21 and 33 to 36 wherein multiple nucleic acid molecules are cleaved.

38. A system for exonuclease-mediated mass spectrometric sequencing, comprising

- (i) reactor means for containing exonuclease cleavage reactions of the target nucleic acids, the cleavage

reaction forming a train of sequentially released individual nucleotides;  
 (ii) mass spectrometric means for detecting the train of individual nucleotides released by the exonuclease cleavage of the target nucleic acid; and  
 (iii) transfer means for transferring the train of individual nucleotides from the reactor means to the mass spectrometric means.

39. The system of claim 38 wherein the transfer means further comprises a moving belt.

40. The system of claim 38 or claim 39 wherein the reactor means further comprises a reactor with a cooling/heating mantle for controlling the temperature of the exonuclease cleavage reaction, at least one reagent flask for providing at least one reagent to the reactor, at least one pumping device for pumping the reagents and reactants to and from the reactor, at least one heating/cooling coil for controlling the temperature of reagents provided to the reactor and means for immobilizing one of the target nucleic acids or the exonuclease in the reactor.

41. The system according to claim 39 in which the moving belt comprises an endless moving belt driven by a stepping motor and held under tension by spring-loaded pulleys, a sample application area for applying a sample of the individual nucleotides released by the exonuclease cleavage of the target nucleic acids to a portion of the moving belt, a cooling/heating plate positioned beneath the sample application area or controlling the temperature of the sample application area, a CCD camera with optics for viewing the sample application area, a source for ionization/desorption capable of moving across the surface of the belt in a direction perpendicular to the motion of the moving belt, differential vacuum pumping stages for generating a vacuum over a portion of the moving belt, and a heating device to facilitate removal of sample residue from the moving belt.

42. The system of claim 41 (a) further comprising a washing station to wash the moving belt with a cleaning solution prior to application of the sample, wherein the heating device facilitates drying the belt after rinsing with the cleaning solution; or (b) wherein the heating device is a microwave; or (c) wherein the source for ionization/desorption is a laser.

43. The system according to any one of claims 38 to 42 further comprising (a) a plurality of reactor means for parallel sequencing of a plurality of nucleic acids; or (b) a microprocessor for processing the detected train of released nucleotides and determining the sequence of the target nucleic acids.

44. The system of claim 40 wherein the reactor means further comprises at least one secondary reactor for mass-modifying the individual nucleotides released by the exonuclease cleavage of the target nucleic acids.

45. The system of claim 44 wherein the secondary reactor comprises immobilized alkaline phosphatase.

**Claims for the following Contracting States : NL, BE, AT, LU, ES, GR, DK, MC, PT, IE**

1. A method of determining a sequence of a nucleic acid, comprising

- (i) isolating the nucleic acid to be sequenced;
- (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to sequentially release individual nucleotides;
- (iii) identifying each of the sequentially released nucleotides by mass spectrometry; and
- (iv) determining the sequence of the nucleic acid from the identified nucleotides.

2. The method according to claim 1 wherein the nucleic acid is a 2'-deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA).

3. The method according to claim 1 or claim 2 wherein the exonuclease activity is selected from a group consisting of snake venom phosphodiesterase, spleen phosphodiesterase, Bal-31 nuclease, *E. coli* exonuclease I, *E. coli* exonuclease VII, Mung Bean Nuclease, S1 Nuclease, an exonuclease activity of *E. coli* DNA polymerase I, an exonuclease activity of a Klenow fragment of DNA polymerase I, an exonuclease activity of T4 DNA polymerase, an exonuclease activity of T7 DNA polymerase, an exonuclease activity of Taq DNA polymerase, an exonuclease activity of Deep Vent® DNA polymerase, exonuclease III, exonuclease and an exonuclease activity of Vent® DNA polymerase.

4. The method according to any one of claims 1, 2 and 3 wherein the exonuclease activity is immobilized by covalent attachment to a solid support, entrapment within a gel matrix or contained in a reactor with a semipermeable membrane.
- 5 5. The method according to claim 4 wherein the solid support for the exonuclease activity is (a) a capillary and the exonuclease activity is covalently attached to the inner wall of the capillary; or (b) selected from the group consisting of glass beads, cellulose beads, polystyrene beads, Sephadex® beads, Sepharose® beads, polyacrylamide beads and agarose beads; or (c) a flat membrane.
- 10 6. The method according to any one of claims 1, 2 and 3 wherein the isolated nucleic acid is immobilized by covalent attachment to a solid support and the exonuclease activity is in a solution contacted with the immobilized nucleic acid.
- 15 7. The method of claim 6 wherein the solid support for the nucleic acid is (a) a capillary and the nucleic acid is covalently attached to the inner wall of the capillary; or (b) selected from the group consisting of glass beads, cellulose beads, polystyrene beads, Sephadex® beads, Sepharose® beads, polyacrylamide beads and agarose beads; or (c) a flat membrane.
- 20 8. The method according to any one of the preceding claims wherein the nucleic acid comprises mass-modified nucleotides.
9. The method according to any one of claims 1 to 8 wherein said sequentially released nucleotides are mass-modified subsequent to exonuclease release and prior to mass spectrometric identification.
- 25 10. The method according to claim 9 wherein sequential release is effected by contact with alkaline phosphatase.
11. The method according to claim 8 wherein the mass-modified nucleotides modulate the rate of exonuclease activity.
- 30 12. The method according to any one of the preceding claims wherein i different species of nucleic acids are concurrently sequenced by multiplex mass spectrometric sequencing and the sequential released nucleotides from each species of the i nucleic acids can be distinguished by mass spectrometry from the sequentially released nucleotides from the remaining i-1 nucleic acids based on a difference in mass due to mass-modification of at least a portion of the sequentially released nucleotides.
- 35 13. The method according to claim 12 wherein the mass-modified nucleotides modulate the rate of exonuclease activity.
- 40 14. The method according to claim 12 wherein the mass-modified nucleotide comprises a mass-modifying functionality (M) attached to the sequentially released nucleotide.
- 45 15. The method according to claim 12 wherein (a) at least one of the mass-modified nucleotides is modified with a mass modifying functionality (M) attached to a 5' phosphate; or (b) at least one of the mass-modified nucleotides is modified with a mass-modifying functionality (M) attached to a C-2' position of a sugar moiety; or (c) at least one of the mass-modified nucleotides is modified with a mass modifying functionality (M) attached to a heterocyclic base.
- 50 16. The method of claim 15 wherein the mass-modified nucleotide comprises a modified heterocyclic base selected from the group consisting of a cytosine moiety modified at C-5, an uracil moiety modified at C-5, a thymine moiety modified at the C-5 methyl group, an adenine moiety modified at C-8, a c7-deazaadenine moiety modified at C-8, a c7-deazaadenine moiety modified at C-7, a guanine moiety modified at C-8, a c7-deazaguanine moiety modified at C-8, a c7-deazaguanine moiety modified at C-7, a hypoxanthine moiety modified at C-8, a c7-deazahypoxanthine moiety modified at C-8 and a c7-deazahypoxanthine moiety modified at C-7.
- 55 17. The method according to claim 8 wherein the mass-modified nucleic acid is prepared from a single-stranded template polynucleotide complementary to the nucleic acid sequence by synthesizing the nucleic acid using mass-modified nucleotides.
18. The method of claim 17 wherein (a) the mass-modified nucleic acid is synthesized using a DNA polymerase and



mass-modified deoxyribonucleoside triphosphates (dNTPs); or (b) the mass-modified nucleic acid is synthesized using a RNA polymerase and mass-modified ribonucleoside triphosphates (NTPs).

- 5 19. The method according to claim 17 wherein (a) the mass-modified nucleic acid is synthesized using a primer having a sequence which allows the nucleic acid to be anchored to the solid support; or (b) synthesis of the nucleic acid is initiated in the presence of an initiator oligonucleotide having a 5'-functionality allowing the nucleic acid to be immobilized on the solid support.
- 10 20. The method according to claim 6 wherein the nucleic acid further comprises a linking group (L) for covalently attaching the nucleic acid to the solid support.
- 15 21. The method of claim 20 wherein the solid support further comprises a splint oligonucleotide and the linking group (L) comprises a nucleotide sequence able to anneal to the splint oligonucleotide and be covalently attached to the solid support by action of a ligase activity.
- 20 22. A kit for sequencing nucleic acids by exonuclease-mediated by mass spectrometry, comprising
  - (i) an exonuclease activity for cleaving the nucleic acids unilaterally from a first end to sequentially release individual nucleotides;
  - (ii) a set of nucleotides for synthesizing the nucleic acid;
  - (iii) a polymerase for synthesizing the nucleic acid from a complementary template and the set of nucleotides; and
  - (iv) a solid support for immobilizing the nucleic acid or the exonuclease wherein at least a portion of the set of nucleotides is mass modified to modulate cleavage activity of the exonuclease.
- 25 23. The kit according to claim 22 wherein the nucleic acids further comprise at least two different species of nucleic acids.
- 30 24. The kit according to claim 22 or 23 wherein the nucleic acids are 2' deoxyribonucleic acids (DNA) or ribonucleic acids (RNA).
- 35 25. The kit according to any one of claims 22, 23 or 24 wherein the exonuclease activity is selected from a group consisting of snake venom phosphodiesterase, spleen phosphodiesterase, Bal-31 nuclease, *E. coli* exonuclease I, *E. coli* exonuclease VII, Mung Bean Nuclease, S1 nuclease, an exonuclease activity of *E. coli* DNA polymerase I, an exonuclease activity of a Klenow fragment of DNA polymerase I, an exonuclease activity of T4 DNA polymerase, an exonuclease activity of T7 DNA polymerase, an exonuclease activity of Taq DNA polymerase, an exonuclease activity of Deep Vent® DNA polymerase, exonuclease, exonuclease III and an exonuclease activity of Vent® DNA polymerase.
- 40 26. The kit according to any one of claims 22 to 25 wherein the solid support is selected from the group consisting of a capillary, a flat membrane, glass beads, cellulose beads, polystyrene beads, Sephadex® beads, Sepharose® beads, polyacrylamide beads and agarose beads.
- 45 27. The kit according to any one of claims 22 to 26 wherein the solid support is functionalized to facilitate covalent attachment of the nucleic acids.
28. The kit according to any one of claims 22 to 27 wherein the exonuclease activity is immobilized by covalent attachment to the solid support.
- 50 29. The kit according to anyone of 22-28 claims wherein the mass-modified nucleotide comprise a mass-modified functionality (M) attached to a nucleotide moiety.
- 55 30. The kit according to claim 29 wherein the mass-modifying functionality (M) is attached to a nucleotide moiety at a position selected from a group consisting of a 5' phosphate, a C-2' position of a sugar moiety and a heterocyclic base.
31. The kit according to any one of claims 22 to 30 further comprising an instruction manual providing the exonuclease sequencing protocol.

32. A kit according to any one of claims 22 to 31 wherein at least a portion of the set of nucleotides is mass-modified such that sequentially released nucleotides of each of the different species are distinguishable.
33. A method of determining a sequence of a nucleic acid, comprising
- (i) isolating the nucleic acid to be sequenced;
  - (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to produce a set of nucleic acid fragments;
  - (iii) identifying the molecular weight value of each one of the set of nucleic acid fragments by mass spectrometry; and
  - (iv) determining the sequence of the nucleic acid from the molecular weight values of the set of nucleic acid fragments; wherein the isolated nucleic acid is immobilized by covalent attachment to a solid support.
34. The method according to claim 33 wherein the nucleic acid is a 2'-deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA).
35. The method according to claim 33 or claim 34 wherein the exonuclease activity is selected from the group consisting of snake venom phosphodiesterase, spleen phosphodiesterase, Bal-31 nuclease, *E. coli* exonuclease I, *E. coli* exonuclease VII, Mung Bean Nuclease, S1 Nuclease, an exonuclease activity of *E. coli* DNA polymerase I, an exonuclease activity of the Klenow fragment of DNA polymerase I, an exonuclease activity of T4 DNA polymerase, an exonuclease activity of T7 DNA polymerase, an exonuclease activity of Taq DNA polymerase, an exonuclease activity of Deep Vent® DNA polymerase, exonuclease III, exonuclease and an exonuclease activity of Vent® DNA polymerase.
36. The method of any one of claims 33 to 35 wherein the nucleic acid comprises mass-modified nucleotides.
37. A method according to any of claims 1 to 21 and 33 to 36 wherein multiple nucleic acid molecules are cleaved.
38. A system for exonuclease-mediated mass spectrometric sequencing, comprising
- (i) reactor means for containing exonuclease cleavage reactions of the target nucleic acids, the cleavage reaction forming a train of sequentially released individual nucleotides;
  - (ii) mass spectrometric means for detecting the train of individual nucleotides released by the exonuclease cleavage of the target nucleic acid; and
  - (iii) transfer means for transferring the train of individual nucleotides from the reactor means to the mass spectrometric means.
39. The system of claim 38, wherein the transfer means further comprises a moving belt.
40. The system of claim 38 or claim 39 wherein the reactor means further comprises a reactor with a cooling/heating mantle for controlling the temperature of the exonuclease cleavage reaction, at least one reagent flask for providing at least one reagent to the reactor, at least one pumping device for pumping the reagents and reactants to and from the reactor, at least one heating/cooling coil for controlling the temperature of reagents provided to the reactor and means for immobilizing one of the target nucleic acids or the exonuclease in the reactor.
41. The system according to claim 39 in which the moving belt comprises an endless moving belt driven by a stepping motor and held under tension by spring-loaded pulleys, a sample application area for applying a sample of the individual nucleotides released by the exonuclease cleavage of the target nucleic acids to a portion of the moving belt, a cooling/heating plate positioned beneath the sample application area or controlling the temperature of the sample application area, a CCD camera with optics for viewing the sample application area, a source for ionization/desorption capable of moving across the surface of the belt in a direction perpendicular to the motion of the moving belt, differential vacuum pumping stages for generating a vacuum over a portion of the moving belt, and a heating device to facilitate removal of sample residue from the moving belt.
42. The system of claim 41 (a) further comprising a washing station to wash the moving belt with a cleaning solution prior to application of the sample, wherein the heating device facilitates drying the belt after rinsing with the cleaning solution; or (b) wherein the heating device is a microwave; or (c) wherein the source for ionization/desorption is a laser.

43. The system according to any one of claims 38 to 42 further comprising (a) a plurality of reactor means for parallel sequencing of a plurality of nucleic acids; or (b) a microprocessor for processing the detected train of released nucleotides and determining the sequence of the target nucleic acids.
- 5 44. The system of claim 40, wherein the reactor means further comprises at least one secondary reactor for mass-modifying the individual nucleotides released by the exonuclease cleavage of the target nucleic acids.
45. The system of claim 44 wherein the secondary reactor comprises immobilized alkaline phosphatase.
- 10 46. A method of determining a sequence of a nucleic acid, comprising
- (i) isolating the nucleic acid to be sequenced;
  - (ii) cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to produce a set of nested nucleic acid fragments;
  - 15 (iii) Identifying the molecular weight value of each one of the set of nucleic acid fragments by mass spectrometry; and
  - (iv) determining the sequence of the nucleic acid from the molecular weight values of the set of nucleic acid fragments.

20

## Patentansprüche

25

Patentansprüche für folgende Vertragsstaaten : CH, DE, FR, GB, IT, LI, SE

1. Verfahren zum Bestimmen einer Sequenz einer Nukleinsäure, wobei das Verfahren umfasst:
- (i) Isolieren der zu sequenzierenden Nukleinsäure;
  - (ii) Spalten der Nukleinsäure von einer Seite von einem ersten Ende mit einer Exonuklease-Aktivität, um sequentiell individuelle Nukleotide freizusetzen;
  - 30 (iii) Messen der Masse von jedem der sequentiell freigesetzten Nukleotide durch Massenspektrometrie, um deren Identität anzuzeigen; und
  - (iv) Bestimmen der Nukleinsäuresequenz anhand der identifizierten Nukleotide.
- 35 2. Verfahren gemäß Anspruch 1, wobei die Nukleinsäure eine 2'-Desoxyribonukleinsäure (DNA) oder eine Ribonukleinsäure (RNA) ist.
3. Verfahren gemäß Anspruch 1 oder Anspruch 2, wobei die Exonuklease-Aktivität aus einer Gruppe ausgewählt wird, die aus Schlangengift-Phosphodiesterase, Milz-Phosphodiesterase, Bal-31 Nuklease, *E. coli* Exonuklease I, *E. coli* Exonuklease VII, Mungbohnen-Nuklease, S1 Nuklease, einer Exonuklease-Aktivität von *E. coli* DNA-Polymerase I, einer Exonuklease-Aktivität eines Klenow Fragments von DNA-Polymerase I, einer Exonuklease-Aktivität von T4 DNA-Polymerase, einer Exonuklease-Aktivität von T7 DNA-Polymerase, einer Exonuklease-Aktivität von Taq DNA-Polymerase, einer Exonuklease-Aktivität von Deep Vent® DNA-Polymerase, Exonuklease III, Exonuklease und einer Exonuklease-Aktivität von Vent® DNA-Polymerase besteht.
- 45 4. Verfahren gemäß einem der Ansprüche 1, 2 und 3, wobei die Exonuklease-Aktivität durch kovalente Verknüpfung an einen festen Träger immobilisiert wird, Einschließen innerhalb einer Gelmatrix oder in einem Reaktor mit einer semipermeablen Membran enthalten ist.
- 50 5. Verfahren gemäß Anspruch 4, wobei der feste Träger für die Exonuklease-Aktivität (a) eine Kapillare ist und die Exonuklease-Aktivität kovalent mit der inneren Wand der Kapillare verknüpft ist; oder (b) aus der Gruppe ausgewählt wird, die aus Glaskügelchen, Zellulosekügelchen, Polystyrolkügelchen, Sephadex®-Kügelchen, Sepharose®-Kügelchen, Polyacrylamidkügelchen und Agarosekügelchen besteht; oder (c) eine flache Membran ist.
- 55 6. Verfahren gemäß einem der Ansprüche 1, 2 und 3, wobei die isolierte Nukleinsäure durch kovalente Verknüpfung an einen festen Träger immobilisiert wird und die Exonuklease-Aktivität sich in einer Lösung befindet, die mit der immobilisierten Nukleinsäure in Kontakt gebracht wird.

7. Verfahren gemäß Anspruch 6, wobei der feste Träger für die Nukleinsäure (a) eine Kapillare ist und die Nukleinsäure kovalent mit der inneren Wand der Kapillare verknüpft wird; oder (b) aus der Gruppe ausgewählt wird, die aus Glaskügelchen, Zellulosekügelchen, Polystyrolkügelchen, Sephadex®-Kügelchen, Sepharose®-Kügelchen, Polyacrylamidkügelchen und Agarosekügelchen besteht; oder (c) eine flache Membran ist.
8. Verfahren gemäß einem der vorangehenden Ansprüche, wobei die Nukleinsäure massenmodifizierte Nukleotide umfasst.
9. Verfahren gemäß einem der Ansprüche 1 bis 8, wobei die sequentiell freigesetzten Nukleotide im Anschluss an die Exonukleasen-Freisetzung und vor der massenspektrometrischen Identifizierung massenmodifiziert werden.
10. Verfahren gemäß Anspruch 9, wobei die sequentielle Freisetzung durch Kontakt mit alkalischer Phosphatase bewirkt wird.
11. Verfahren gemäß Anspruch 8, wobei die massenmodifizierten Nukleotide die Rate der Exonuklease-Aktivität modulieren.
12. Verfahren gemäß einem der vorangehenden Ansprüche, wobei i unterschiedliche Spezies von Nukleinsäuren gleichzeitig durch vielfaches massenspektrometrisches Sequenzieren sequenziert werden und die sequentiell freigesetzten Nukleotide von jeder Spezies der i Nukleinsäuren durch Massenspektrometrie von den sequentiell freigesetzten Nukleotiden der verbleibenden i-1 Nukleinsäuren auf der Basis eines Massenunterschiedes aufgrund der Massenmodifizierung von mindestens einem Teil der sequentiell freigesetzten Nukleotide unterschieden werden können.
13. Verfahren gemäß Anspruch 12, wobei die massenmodifizierten Nukleotide die Rate der Exonuklease-Aktivität modulieren.
14. Verfahren gemäß Anspruch 12, wobei das massenmodifizierte Nukleotid eine massenmodifizierende Funktionalität (M) umfasst, die an das sequentiell freigesetzte Nukleotid angefügt ist.
15. Verfahren gemäß Anspruch 12, wobei (a) mindestens eines der massenmodifizierten Nukleotide mit einer massenmodifizierenden Funktionalität (M) modifiziert ist, die an ein 5' Phosphat angefügt ist; oder (b) mindestens eines der massenmodifizierten Nukleotide mit einer massenmodifizierenden Funktionalität (M) modifiziert ist, die an eine C-2'-Position einer Zuckergruppe angefügt ist; oder (c) mindestens eines der massenmodifizierten Nukleotide mit einer massenmodifizierenden Funktionalität (M) modifiziert ist, die an eine heterozyklische Base angefügt ist.
16. Verfahren gemäß Anspruch 15, wobei das massenmodifizierte Nukleotid eine modifizierte heterozyklische Base umfasst, die aus der Gruppe ausgewählt wird, die aus einer an C-5 modifizierten Cytosingruppe, einer an C-5 modifizierten Uracilgruppe, einer an der C-5 Methylgruppe modifizierten Thymingruppe, einer an C-8 modifizierten Adeninegruppe, einer an C-8 modifizierten c7-Desazaadeninegruppe, einer an C-7 modifizierten c7-Desazaadeninegruppe, einer an C-8 modifizierten Guaninegruppe, einer an C-8 modifizierten C7-Desazaguaninegruppe, einer an C-7 modifizierten c7-Desazaguaninegruppe, einer an C-8 modifizierten Hypoxanthinegruppe, einer an C-8 modifizierten c7-Desazahypoxanthinegruppe und einer an C-7 modifizierten c7-Desazahypoxanthinegruppe besteht.
17. Verfahren gemäß Anspruch 8, wobei die massenmodifizierte Nukleinsäure aus einem einzelsträngigen zu der Nukleinsäuresequenz komplementären Polynukleotid-Template hergestellt wird, indem man die Nukleinsäure unter Verwendung von massenmodifizierten Nukleotiden synthetisiert.
18. Verfahren gemäß Anspruch 17, wobei (a) die massenmodifizierte Nukleinsäure unter Verwendung einer DNA-Polymerase und massenmodifizierten Desoxyribonukleosid-Triphosphaten (dNTPs) synthetisiert wird; oder (b) die massenmodifizierte Nukleinsäure unter Verwendung einer RNA-Polymerase und massenmodifizierten Ribonukleosid-Triphosphaten (NTPs) synthetisiert ist.
19. Verfahren gemäß Anspruch 17, wobei (a) die massenmodifizierte Nukleinsäure unter Verwendung eines Primers synthetisiert wird, der eine Sequenz besitzt, die es erlaubt, die Nukleinsäure auf dem festen Träger zu verankern; oder (b) die Synthese der Nukleinsäure in Gegenwart eines Initiator-Oligonukleotids initiiert wird, das eine 5'-Funktionalität hat, die es erlaubt, die Nukleinsäure auf dem festen Träger zu immobilisieren.



20. Verfahren gemäß Anspruch 6, wobei die Nukleinsäure ferner eine Linkergruppe (L) zur kovalenten Verknüpfung der Nukleinsäure auf den festen Träger umfasst.
- 5 21. Verfahren gemäß Anspruch 20, wobei der feste Träger weiterhin ein Splint-Oligonukleotid umfasst, und die Linkergruppe (L) eine Nukleotidsequenz umfasst, die in der Lage ist, sich an das Splint Oligonukleotid anzulagern, und kovalent an den festen Träger durch die Wirkung einer Ligase-Aktivität verknüpft zu werden.
22. Kit zum Sequenzieren von Nukleinsäuren durch Exonuklease-vermittelte Massenspektrometrie, das umfasst
  - 10 (i) eine Exonuklease-Aktivität zum Spalten der Nukleinsäuren von einer Seite von einem ersten Ende, um sequentiell individuelle Nukleotide freizusetzen;
  - (ii) einen Satz von Nukleotiden zum Synthetisieren der Nukleinsäure;
  - (iii) eine Polymerase zum Synthetisieren der Nukleinsäure von einem komplementären Template und dem Satz von Nukleotiden; und
  - 15 (iv) einem festen Träger zum Immobilisieren der Nukleinsäure oder der Exonuklease,

wobei mindestens ein Teil des Satzes von Nukleotiden massenmodifiziert ist, um die Freisetzungsektivität der Exonuklease zu modulieren.
- 20 23. Kit gemäß Anspruch 22, wobei die Nukleinsäuren ferner mindestens zwei verschiedene Nukleinsäure-Spezies umfassen.
24. Kit gemäß Ansprüchen 22 oder 23, wobei die Nukleinsäuren 2' Desoxyribonukleinsäuren (DNA) oder Ribonukleinsäuren (RNA) sind.
- 25 25. Kit gemäß Anspruch 22, 23 oder 24, wobei die Exonuklease-Aktivität aus einer Gruppe ausgewählt wird, die aus Schlangengift-Phosphodiesterase, Milz-Phosphodiesterase, Bal-31 Nuklease, *E. coli*-Exonuklease I, *E. coli*-Exonuklease VII, Mungbohnen-Nuklease, S1 Nuklease, einer Exonuklease-Aktivität von *E. coli* DNA-Polymerase I, einer Exonuklease-Aktivität eines Klenow-Fragments von DNA-Polymerase I, einer Exonuklease-Aktivität von T4
  - 30 DNA-Polymerase, einer Exonuklease-Aktivität von T7 DNA-Polymerase, einer Exonuklease-Aktivität von Taq DNA-Polymerase, einer Exonuklease-Aktivität von Deep Vent® DNA-Polymerase, Exonuklease und Exonuklease III und eine Exonuklease-Aktivität von Vent® DNA-Polymerase besteht.
- 35 26. Kit gemäß einem der Ansprüche 22 bis 25, wobei der feste Träger aus der Gruppe ausgewählt wird, die aus einer Kapillare, einer flachen Membran, Glaskügelchen, Zellulosekügelchen, Polystyrolkügelchen, Sephadex®-Kügelchen, Sepharose®-Kügelchen, Polyacrylamidkügelchen und Agarosekügelchen besteht.
27. Kit gemäß einem der Ansprüche 22 bis 26, wobei der feste Träger funktionalisiert ist, um eine kovalente Verknüpfung der Nukleinsäuren zu erleichtern.
- 40 28. Kit gemäß einem der Ansprüche 22 bis 27, wobei die Exonuklease-Aktivität durch kovalente Verknüpfung an den festen Träger immobilisiert ist.
29. Kit gemäß einem der Ansprüche 22 bis 28, wobei das massenmodifizierte Nukleotid eine massenmodifizierte Funktionalität (M) umfasst, die mit einer Nukleotidgruppe verknüpft ist.
- 45 30. Kit gemäß Anspruch 29, wobei die massenmodifizierende Funktionalität (M) mit einer Nukleotidgruppe an einer Position verknüpft ist, die aus einer Gruppe ausgewählt wird, die aus einer 5'Phosphat, einer C-2'Position einer Zuckergruppe und einer heterozyklischen Base besteht.
- 50 31. Kit gemäß einem der Ansprüche 22 bis 30, das ferner eine Gebrauchsanweisung umfasst, die das Exonuklease-Sequenzierungsprotokoll bereitstellt.
- 55 32. Kit gemäß einem der Ansprüche 22 bis 31, wobei mindestens ein Teil des Satzes von Nukleotiden so massenmodifiziert ist, dass sequentiell freigesetzte Nukleotide von jeder der unterschiedlichen Spezies unterscheidbar sind.
33. Verfahren zum Bestimmen einer Sequenz einer Nukleinsäure, das umfasst

- (i) Isolieren der zu sequenzierenden Nukleinsäure;
  - (ii) Spalten der Nukleinsäure von einer Seite von einem ersten Ende mit einer Exonuklease-Aktivität, um einen Satz von Nukleinsäurefragmenten zu erzeugen;
  - (iii) Identifizieren des Molekulargewichtswertes von jedem des Satzes der Nukleinsäurefragmente durch Massenspektrometrie; und
  - (iv) Bestimmen der Sequenz der Nukleinsäure anhand der Molekulargewichtswerte des Satzes von Nukleinsäurefragmenten; wobei die Isolierte Nukleinsäure durch kovalente Verknüpfung an einen festen Träger immobilisiert wird.
34. Verfahren gemäß Anspruch 33, wobei die Nukleinsäure eine 2'-Desoxyribonukleinsäure (DNA) oder Ribonukleinsäure (RNA) ist.
35. Verfahren gemäß Anspruch 33 oder Anspruch 34, wobei die Exonuklease-Aktivität aus der Gruppe ausgewählt wird, die aus Schlangengift-Phosphodiesterase, Milz-Phosphodiesterase, Bal-31 Nuklease, *E. coli*-Exonuklease I, *E. coli*-Exonuklease VII, Mungbohnen-Nuklease, S1-Nuklease, einer Exonuklease-Aktivität von *E. coli* DNA-Polymerase I, einer Exonuklease-Aktivität des Klenow-Fragments von DNA-Polymerase I, einer Exonuklease-Aktivität von T4 DNA-Polymerase, einer Exonuklease-Aktivität von T7 DNA-Polymerase, einer Exonuklease-Aktivität von Taq DNA-Polymerase, einer Exonuklease-Aktivität von Deep Vent® DNA Polymerase, Exonuklease III, Exonuklease und einer Exonuklease-Aktivität von Vent® DNA Polymerase besteht.
36. Verfahren gemäß einem der Ansprüche 33 bis 35, wobei die Nukleinsäure massenmodifizierte Nukleotide umfasst.
37. Verfahren gemäß einem der Ansprüche 1 bis 21 und 33 bis 36, wobei mehrere Nukleinsäuremoleküle gespalten werden.
38. System zum Exonuklease-vermittelten massenspektrometrischen Sequenzieren, das umfasst
- (i) Reaktormittel zum Enthalten der Exonukleasen Spaltungsreaktionen der Zielnukleinsäuren, wobei die Spaltungsreaktion eine Folge von sequentiell freigesetzten individuellen Nukleotiden erzeugt;
  - (ii) massenspektrometrisches Mittel zum Nachweisen der Folge von individuellen Nukleotiden, die durch Exonuklease-Spaltung der Zielnukleinsäure freigesetzt wurden; und
  - (iii) Transferrmittel zum Transferieren der Folge von individuellen Nukleotiden aus dem Reaktormittel zu dem massenspektrometrischen Mittel.
39. System gemäß Anspruch 38, wobei das Transferrmittel ferner ein Fließband umfasst.
40. System gemäß Anspruch 38 oder Anspruch 39, wobei das Reaktormittel ferner einen Reaktor mit einem Kühl/Heizmantel zur Kontrolle der Temperatur der Exonuklease-Spaltungsreaktion, mindestens einen Reagenzienkolben zum Zuführen mindestens eines Reagenzes in den Reaktor, mindestens eine Pumpvorrichtung zum Pumpen der Reagenzien und Reaktanden zum und vom Reaktor, mindestens eine Heiz/Kühlspirale zur Kontrolle der Temperatur der dem Reaktor zugeführten Reagenzien und Mittel zum Immobilisieren einer der Zielnukleinsäuren oder der Exonuklease im Reaktor umfasst.
41. System gemäß Anspruch 39, in dem das Fließband umfasst ein Endlosfließband, das durch einen Schrittmotor betrieben wird und durch gefederte Rollen unter Spannung gehalten wird, einen Probenaufbringungsbereich zum Aufbringen einer Probe der individuellen Nukleotide, die durch die Exonuklease-Spaltung der Zielnukleinsäuren freigesetzt wurden, auf einen Teil des Fließbandes, eine Kühl/Heizplatte, die unterhalb des Probenaufbringungsbereichs angeordnet ist oder die Temperatur des Probenaufbringungsbereichs kontrolliert, eine CCD Kamera mit einer Optik zum Betrachten des Probenaufbringungsbereichs, eine Quelle für Ionisation/Desorption, die in der Lage ist, sich über die Oberfläche des Bandes in einer zur Bewegung des Fließbandes senkrechten Richtung zu bewegen, differentielle Vakuumpumpstufen zum Erzeugen eines Vakuums über einen Teil des Fließbandes, und eine Heizvorrichtung zum Erleichtern des Entferns von Probenrückständen von dem Fließband umfasst.
42. System nach Anspruch 41, (a) das ferner eine Waschstation zum Waschen des Fließbandes mit einer Reinigungslösung vor dem Aufbringen der Probe umfasst, wobei die Heizvorrichtung das Trocknen des Bandes nach dem Reinigen mit der Reinigungslösung erleichtert; oder (b) wobei die Heizvorrichtung eine Mikrowelle ist; oder (c) wobei die Quelle für die Ionisation/Desorption ein Laser ist.

43. System gemäß einem der Ansprüche 38 bis 42, das ferner umfasst (a) eine Mehrzahl von Reaktormitteln zum parallelen Sequenzieren einer Mehrzahl von Nukleinsäuren umfasst; oder (b) einen Mikroprozessor zum Verarbeiten der nachgewiesenen Folge von freigesetzten Nukleotiden und Bestimmen der Sequenz der Zielnukleinsäuren.
- 5 44. System nach Anspruch 40, wobei das Reaktormittel ferner mindestens einen zweiten Reaktor zum Massenmodifizieren der Individuellen Nukleotide, die durch die Exonuklease-Spaltung der Zielnukleinsäuren freigesetzt wurden, umfasst.
- 10 45. System nach Anspruch 44, wobei der zweite Reaktor immobilisierte alkalische Phosphatase umfasst.

Patentansprüche für folgende Vertragsstaaten : NL, BE, AT, LU, ES, GR, DK, MC, PT, IE

- 15 1. Verfahren zum Bestimmen einer Sequenz einer Nukleinsäure, wobei das Verfahren umfasst:
- (i) Isolieren der zu sequenzierenden Nukleinsäure;
  - (ii) Spalten der Nukleinsäure von einer Seite von einem ersten Ende mit einer Exonuklease-Aktivität, um sequentiell Individuelle Nukleotide freizusetzen;
  - 20 (iii) Identifizieren jedes der sequentiell freigesetzten Nukleotide durch Massenspektrometrie; und
  - (iv) Bestimmen der Nukleinsäuresequenz anhand der identifizierten Nukleotide.
2. Verfahren gemäß Anspruch 1, wobei die Nukleinsäure eine 2'-Desoxyribonukleinsäure (DNA) oder eine Ribonukleinsäure (RNA) ist.
- 25 3. Verfahren gemäß Anspruch 1 oder Anspruch 2, wobei die Exonuklease-Aktivität aus einer Gruppe ausgewählt wird, die aus Schlangengift-Phosphodiesterase, Milz-Phosphodiesterase, Bal-31 Nuklease, *E. coli* Exonuklease I, *E. coli* Exonuklease VII, Mungbohnen-Nuklease, S1 Nuklease, einer Exonuklease-Aktivität von *E. coli* DNA-Polymerase I, einer Exonuklease-Aktivität eines Klenow Fragments von DNA-Polymerase I, einer Exonuklease-Aktivität von T4 DNA-Polymerase, einer Exonuklease-Aktivität von T7 DNA-Polymerase, einer Exonuklease-Aktivität von Taq DNA-Polymerase, einer Exonuklease-Aktivität von Deep Vent® DNA-Polymerase, Exonuklease III, Exonuklease und einer Exonuklease-Aktivität von Vent® DNA-Polymerase besteht.
- 30 4. Verfahren gemäß einem der Ansprüche 1, 2 und 3, wobei die Exonuklease-Aktivität durch kovalente Verknüpfung an einen festen Träger immobilisiert wird, Einschließen innerhalb einer Gelmatrix oder in einem Reaktor mit einer semipermeablen Membran enthalten ist.
- 35 5. Verfahren gemäß Anspruch 4, wobei der feste Träger für die Exonuklease-Aktivität (a) eine Kapillare ist und die Exonuklease-Aktivität kovalent mit der inneren Wand der Kapillare verknüpft ist; oder (b) aus der Gruppe ausgewählt wird, die aus Glaskügelchen, Zellulosekügelchen, Polystyrolkügelchen, Sephadex®-Kügelchen, Sepharose®-Kügelchen, Polyacrylamidkügelchen und Agarosekügelchen besteht; oder (c) eine flache Membran ist.
- 40 6. Verfahren gemäß einem der Ansprüche 1, 2 und 3, wobei die isolierte Nukleinsäure durch kovalente Verknüpfung an einen festen Träger immobilisiert wird und die Exonuklease-Aktivität sich in einer Lösung befindet, die mit der immobilisierten Nukleinsäure in Kontakt gebracht wird.
- 45 7. Verfahren gemäß Anspruch 6, wobei der feste Träger für die Nukleinsäure (a) eine Kapillare ist und die Nukleinsäure kovalent mit der inneren Wand der Kapillare verknüpft wird; oder (b) aus der Gruppe ausgewählt wird, die aus Glaskügelchen, Zellulosekügelchen, Polystyrolkügelchen, Sephadex®-Kügelchen, Sepharose®-Kügelchen, Polyacrylamidkügelchen und Agarosekügelchen besteht; oder (c) eine flache Membran ist.
- 50 8. Verfahren gemäß einem der vorangehenden Ansprüche, wobei die Nukleinsäure massenmodifizierte Nukleotide umfasst.
- 55 9. Verfahren gemäß einem der Ansprüche 1 bis 8, wobei die sequentiell freigesetzten Nukleotide im Anschluss an die Exonukleasen-Freisetzung und vor der massenspektrometrischen Identifizierung massenmodifiziert werden.
10. Verfahren gemäß Anspruch 9, wobei die sequentielle Freisetzung durch Kontakt mit alkalischer Phosphatase be-

wirkt wird.

11. Verfahren gemäß Anspruch 8, wobei die massenmodifizierten Nukleotide die Rate der Exonuklease-Aktivität modulieren.
12. Verfahren gemäß einem der vorangehenden Ansprüche, wobei i unterschiedliche Spezies von Nukleinsäuren gleichzeitig durch vielfaches massenspektrometrisches Sequenzieren sequenziert werden und die sequentiell freigesetzten Nukleotide von jeder Spezies der i Nukleinsäuren durch Massenspektrometrie von den sequentiell freigesetzten Nukleotiden der verbleibenden i-1 Nukleinsäuren auf der Basis eines Massenunterschiedes aufgrund der Massenmodifizierung von mindestens einem Teil der sequentiell freigesetzten Nukleotide unterschieden werden können.
13. Verfahren gemäß Anspruch 12, wobei die massenmodifizierten Nukleotide die Rate der Exonuklease-Aktivität modulieren.
14. Verfahren gemäß Anspruch 12, wobei das massenmodifizierte Nukleotid eine massenmodifizierende Funktionalität (M) umfasst, die an das sequentiell freigesetzte Nukleotid angefügt ist.
15. Verfahren gemäß Anspruch 12, wobei (a) mindestens eines der massenmodifizierten Nukleotide mit einer massenmodifizierenden Funktionalität (M) modifiziert ist, die an ein 5' Phosphat angefügt ist; oder (b) mindestens eines der massenmodifizierten Nukleotide mit einer massenmodifizierenden Funktionalität (M) modifiziert ist, die an eine C-2'-Position einer Zuckergruppe angefügt ist; oder (c) mindestens eines der massenmodifizierten Nukleotide mit einer massenmodifizierenden Funktionalität (M) modifiziert ist, die an eine heterozyklische Base angefügt ist.
16. Verfahren gemäß Anspruch 15, wobei das massenmodifizierte Nukleotid eine modifizierte heterozyklische Base umfasst, die aus der Gruppe ausgewählt wird, die aus einer an C-5 modifizierten Cytosingruppe, einer an C-5 modifizierten Uracilgruppe, einer an der C-5 Methylgruppe modifizierten Thymingruppe, einer an C-8 modifizierten Adeninegruppe, einer an C-8 modifizierten c7-Desazaadeninegruppe, einer an C-7 modifizierten c7-Desazaadeninegruppe, einer an C-8 modifizierten Guaninegruppe, einer an C-8 modifizierten C7-Desazaguaninegruppe, einer an C-7 modifizierten c7-Desazaguaninegruppe, einer an C-8 modifizierten Hypoxanthinegruppe, einer an C-8 modifizierten c7-Desazahypoxanthinegruppe und einer an C-7 modifizierten c7-Desazahypoxanthinegruppe besteht.
17. Verfahren gemäß Anspruch 8, wobei die massenmodifizierte Nukleinsäure aus einem einzelsträngigen zu der Nukleinsäuresequenz komplementären Polynukleotid-Template hergestellt wird, indem man die Nukleinsäure unter Verwendung von massenmodifizierten Nukleotiden synthetisiert.
18. Verfahren gemäß Anspruch 17, wobei (a) die massenmodifizierte Nukleinsäure unter Verwendung einer DNA-Polymerase und massenmodifizierten Desoxyribonukleosid-Triphosphaten (dNTPs) synthetisiert wird; oder (b) die massenmodifizierte Nukleinsäure unter Verwendung einer RNA-Polymerase und massenmodifizierten Ribonukleosid-Triphosphaten (NTPs) synthetisiert ist.
19. Verfahren gemäß Anspruch 17, wobei (a) die massenmodifizierte Nukleinsäure unter Verwendung eines Primers synthetisiert wird, der eine Sequenz besitzt, die es erlaubt, die Nukleinsäure auf dem festen Träger zu verankern; oder (b) die Synthese der Nukleinsäure in Gegenwart eines Initiator-Oligonukleotids initiiert wird, das eine 5'-Funktionalität hat, die es erlaubt, die Nukleinsäure auf dem festen Träger zu immobilisieren.
20. Verfahren gemäß Anspruch 8, wobei die Nukleinsäure ferner eine Linkergruppe (L) zur kovalenten Verknüpfung der Nukleinsäure auf den festen Träger umfasst.
21. Verfahren gemäß Anspruch 20, wobei der feste Träger weiterhin ein Splint-Oligonukleotid umfasst, und die Linkergruppe (L) eine Nukleotidsequenz umfasst, die in der Lage ist, sich an das Splint Oligonukleotid anzulagern, und kovalent an den festen Träger durch die Wirkung einer Ligase-Aktivität verknüpft zu werden.
22. Kit zum Sequenzieren von Nukleinsäuren durch Exonuklease-vermittelte Massenspektrometrie, das umfasst  
(i) eine Exonuklease-Aktivität zum Spalten der Nukleinsäuren von einer Seite von einem ersten Ende, um sequentiell individuelle Nukleotide freizusetzen;  
(ii) einen Satz von Nukleotiden zum Synthetisieren der Nukleinsäure;



- (iii) eine Polymerase zum Synthetisieren der Nukleinsäure von einem komplementären Template und dem Satz von Nukleotiden; und
- (iv) einem festen Träger zum Immobilisieren der Nukleinsäure oder der Exonuklease,

5 wobei mindestens ein Teil des Satzes von Nukleotiden massenmodifiziert ist, um die Freisetzungsaktivität der Exonuklease zu modulieren.

23. Kit gemäß Anspruch 22, wobei die Nukleinsäuren ferner mindestens zwei verschiedene Nukleinsäure-Spezies umfassen.

10 24. Kit gemäß Ansprüchen 22 oder 23, wobei die Nukleinsäuren 2' Desoxyribonukleinsäuren (DNA) oder Ribonukleinsäuren (RNA) sind.

15 25. Kit gemäß Anspruch 22, 23 oder 24, wobei die Exonuklease-Aktivität aus einer Gruppe ausgewählt wird, die aus Schlangengift-Phosphodiesterase, Milz-Phosphodiesterase, Bal-31 Nuklease, *E. coli*-Exonuklease I, *E. coli*-Exonuklease VII, Mungbohnen-Nuklease, S1 Nuklease, einer Exonuklease-Aktivität von *E. coli* DNA-Polymerase I, einer Exonuklease-Aktivität eines Klenow-Fragments von DNA-Polymerase I, einer Exonuklease-Aktivität von T4 DNA-Polymerase, einer Exonuklease-Aktivität von T7 DNA-Polymerase, einer Exonuklease-Aktivität von Taq DNA-Polymerase, einer Exonuklease-Aktivität von Deep Vent® DNA-Polymerase, Exonuklease und Exonuklease III und eine Exonuklease-Aktivität von Vent® DNA-Polymerase besteht.

20 26. Kit gemäß einem der Ansprüche 22 bis 25, wobei der feste Träger aus der Gruppe ausgewählt wird, die aus einer Kapillare, einer flachen Membran, Glaskügelchen, Zellulosekügelchen, Polystyrolkügelchen, Sephadex®-Kügelchen, Sepharose®-Kügelchen, Polyacrylamidkügelchen und Agarosekügelchen besteht.

25 27. Kit gemäß einem der Ansprüche 22 bis 26, wobei der feste Träger funktionalisiert ist, um eine kovalente Verknüpfung der Nukleinsäuren zu erleichtern.

30 28. Kit gemäß einem der Ansprüche 22 bis 27, wobei die Exonuklease-Aktivität durch kovalente Verknüpfung an den festen Träger immobilisiert ist.

29. Kit gemäß einem der Ansprüche 22 bis 28, wobei das massenmodifizierte Nukleotid eine massenmodifizierte Funktionalität (M) umfasst, die mit einer Nukleotidgruppe verknüpft ist.

35 30. Kit gemäß Anspruch 29, wobei die massenmodifizierende Funktionalität (M) mit einer Nukleotidgruppe an einer Position verknüpft ist, die aus einer Gruppe ausgewählt wird, die aus einer 5'Phosphat, einer C-2'Position einer Zuckergruppe und einer heterozyklischen Base besteht.

40 31. Kit gemäß einem der Ansprüche 22 bis 30, das ferner eine Gebrauchsanweisung umfasst, die das Exonuklease-Sequenzierungsprotokoll bereitstellt.

32. Kit gemäß einem der Ansprüche 22 bis 31, wobei mindestens ein Teil des Satzes von Nukleotiden so massenmodifiziert ist, dass sequentiell freigesetzte Nukleotide von jeder der unterschiedlichen Spezies unterscheidbar sind.

45 33. Verfahren zum Bestimmen einer Sequenz einer Nukleinsäure, das umfasst

- (i) Isolieren der zu sequenzierenden Nukleinsäure;
- (ii) Spalten der Nukleinsäure von einer Seite von einem ersten Ende mit einer Exonuklease-Aktivität, um einen Satz von Nukleinsäurefragmenten zu erzeugen;
- 50 (iii) Identifizieren des Molekulargewichtswertes von jedem des Satzes der Nukleinsäurefragmente durch Massenspektrometrie; und
- (iv) Bestimmen der Sequenz der Nukleinsäure anhand der Molekulargewichtswerte des Satzes von Nukleinsäurefragmenten; wobei die isolierte Nukleinsäure durch kovalente Verknüpfung an einen festen Träger immobilisiert wird.

55 34. Verfahren gemäß Anspruch 33, wobei die Nukleinsäure eine 2'-Desoxyribonukleinsäure (DNA) oder Ribonukleinsäure (RNA) ist.

35. Verfahren gemäß Anspruch 33 oder Anspruch 34, wobei die Exonuklease-Aktivität aus der Gruppe ausgewählt wird, die aus Schlangengift-Phosphodiesterase, Milz-Phosphodiesterase, Bal-31 Nuklease, *E. coli*-Exonuklease I, *E. coli*-Exonuklease VII, Mungbohnen-Nuklease, S1-Nuklease, einer Exonuklease-Aktivität von *E. coli* DNA-Polymerase I, einer Exonuklease-Aktivität des Klenow-Fragments von DNA-Polymerase I, einer Exonuklease-Aktivität von T4 DNA-Polymerase, einer Exonuklease-Aktivität von T7 DNA-Polymerase, einer Exonuklease-Aktivität von Taq DNA-Polymerase, einer Exonuklease-Aktivität von Deep Vent® DNA Polymerase, Exonuklease III, Exonuklease und einer Exonuklease-Aktivität von Vent® DNA Polymerase besteht.  
5
36. Verfahren gemäß einem der Ansprüche 33 bis 35, wobei die Nukleinsäure massenmodifizierte Nukleotide umfasst.  
10
37. Verfahren gemäß einem der Ansprüche 1 bis 21 und 33 bis 36, wobei mehrere Nukleinsäuremoleküle gespalten werden.
38. System zum Exonuklease-vermittelten massenspektrometrischen Sequenzieren, das umfasst  
15
  - (i) Reaktormittel zum Enthalten der Exonukleasen Spaltungsreaktionen der Zielnukleinsäuren, wobei die Spaltungsreaktion eine Folge von sequentiell freigesetzten individuellen Nukleotiden erzeugt;
  - (ii) massenspektrometrisches Mittel zum Nachweisen der Folge von individuellen Nukleotiden, die durch Exonuklease-Spaltung der Zielnukleinsäure freigesetzt wurden; und  
20
  - (iii) Transfermittel zum Transferieren der Folge von individuellen Nukleotiden aus dem Reaktormittel zu dem massenspektrometrischen Mittel.
39. System gemäß Anspruch 38, wobei das Transfermittel ferner ein Fließband umfasst.
40. System gemäß Anspruch 38 oder Anspruch 39, wobei das Reaktormittel ferner einen Reaktor mit einem Kühl/Heizmantel zur Kontrolle der Temperatur der Exonuklease-Spaltungsreaktion, mindestens einen Reagenzienkolben zum Zuführen mindestens eines Reagenzes in den Reaktor, mindestens eine Pumpvorrichtung zum Pumpen der Reagenzien und Reaktanden zum und vom Reaktor, mindestens eine Heiz/Kühlspirale zur Kontrolle der Temperatur der dem Reaktor zugeführten Reagenzien und Mittel zum Immobilisieren einer der Zielnukleinsäuren oder der Exonuklease im Reaktor umfasst.  
30
41. System gemäß Anspruch 39, in dem das Fließband umfasst ein Endlosfließband, das durch einen Schrittmotor betrieben wird und durch gefederte Rollen unter Spannung gehalten wird, einen Probenaufbringungsbereich zum Aufbringen einer Probe der individuellen Nukleotide, die durch die Exonuklease-Spaltung der Zielnukleinsäuren freigesetzt wurden, auf einen Teil des Fließbandes, eine Kühl/Heizplatte, die unterhalb des Probenaufbringungsbereichs angeordnet ist oder die Temperatur des Probenaufbringungsbereichs kontrolliert, eine CCD Kamera mit einer Optik zum Betrachten des Probenaufbringungsbereichs, eine Quelle für Ionisation/Desorption, die in der Lage ist, sich über die Oberfläche des Bandes in einer zur Bewegung des Fließbandes senkrechten Richtung zu bewegen, differentielle Vakuumpumpstufen zum Erzeugen eines Vakuums über einen Teil des Fließbandes, und eine Heizvorrichtung zum Erleichtern des Entfernens von Probenrückständen von dem Fließband umfasst.  
35
42. System nach Anspruch 41, (a) das ferner eine Waschstation zum Waschen des Fließbandes mit einer Reinigungslösung vor dem Aufbringen der Probe umfasst, wobei die Heizvorrichtung das Trocknen des Bandes nach dem Reinigen mit der Reinigungslösung erleichtert; oder (b) wobei die Heizvorrichtung eine Mikrowelle ist; oder (c) wobei die Quelle für die Ionisation/Desorption ein Laser ist.  
40
43. System gemäß einem der Ansprüche 38 bis 42, das ferner umfasst (a) eine Mehrzahl von Reaktormitteln zum parallelen Sequenzieren einer Mehrzahl von Nukleinsäuren umfasst; oder (b) einen Mikroprozessor zum Verarbeiten der nachgewiesenen Folge von freigesetzten Nukleotiden und Bestimmen der Sequenz der Zielnukleinsäuren.  
45
44. System nach Anspruch 40, wobei das Reaktormittel ferner mindestens einen zweiten Reaktor zum Massenmodifizieren der individuellen Nukleotide, die durch die Exonuklease-Spaltung der Zielnukleinsäuren freigesetzt wurden, umfasst.  
50
45. System nach Anspruch 44, wobei der zweite Reaktor immobilisierte alkalische Phosphatase umfasst.  
55
46. Verfahren zum Bestimmen einer Sequenz einer Nukleinsäure, wobei das Verfahren umfasst:

- (i) Isolieren der zu sequenzierenden Nukleinsäure;
- (ii) Spalten der Nukleinsäure von einer Seite von einem ersten Ende mit einer Exonuklease-Aktivität, um einen Satz an verschachtelten Nukleinsäurefragmenten zu erzeugen;
- (iii) Identifizieren der Molekulargewichtswerte von jedem des Satz der Nukleinsäurefragmente durch Massenspektrometrie; und
- (iv) Bestimmen der Nukleinsäuresequenz anhand der Molekulargewichtswerte des Satzes der Nukleinsäurefragmente.

## 10 Revendications

Revendications pour les Etats contractants suivants : CH, DE, FR, GB, IT, LI, SE

- 15 1. Méthode pour la détermination d'une séquence d'un acide nucléique, comprenant les étapes consistant
  - (i) à isoler l'acide nucléique à séquencer ;
  - (ii) à cliver l'acide nucléique unilatéralement par une première extrémité avec une activité d'exonuclease pour libérer de manière séquentielle des nucléotides distincts ;
  - 20 (iii) à mesurer la masse de chacun des nucléotides libérés de manière séquentielle par spectrométrie de masse pour déterminer leur identité ; et
  - (iv) à déterminer la séquence de l'acide nucléique d'après les nucléotides identifiés.
- 25 2. Méthode suivant la revendication 1, dans laquelle l'acide nucléique est un acide 2'-désoxyribonucléique (ADN) ou un acide ribonucléique (ARN).
3. Méthode suivant la revendication 1 ou la revendication 2, dans laquelle l'activité d'exonuclease est choisie dans le groupe consistant en la phosphodiesterase de venin de serpent, la phosphodiesterase de rate, la nucléase Bal-31, l'exonuclease I de *E. coli*, l'exonuclease VII de *E. coli*, la nucléase de haricot Mung, la nucléase S1, une activité d'exonuclease d'ADN-polymérase I de *E. coli*, une activité d'exonuclease d'un fragment de Klenow d'ADN-polymérase I, une activité d'exonuclease d'ADN-polymérase T4, une activité d'exonuclease d'ADN-polymérase T7, une activité d'exonuclease d'ADN-polymérase Taq, une activité d'exonuclease d'ADN-polymérase Deep Vent®, l'exonuclease III, l'exonuclease et une activité d'exonuclease d'ADN-polymérase Vent®.
- 35 4. Méthode suivant l'une quelconque des revendications 1, 2 et 3, dans laquelle l'activité d'exonuclease est immobilisée par fixation covalente à un support solide, pléageage dans une matrice de gel ou introduction dans un réacteur muni d'une membrane semi-perméable.
- 40 5. Méthode suivant la revendication 4, dans laquelle le support solide pour l'activité d'exonuclease est (a) un capillaire et l'activité d'exonuclease est fixée par covalence à la paroi intérieure du capillaire ; ou (b) choisi dans le groupe consistant en des billes de verre, des billes de cellulose, des billes de polystyrène, des billes de Sephadex®, des billes de Sepharose®, des billes de polyacrylamide et des billes d'agarose ; et (c) une membrane plate.
- 45 6. Méthode suivant l'une quelconque des revendications 1, 2 et 3, dans laquelle l'acide nucléique isolé est immobilisé par fixation covalente à un support solide et l'activité d'exonuclease est présente dans une solution en contact avec l'acide nucléique immobilisé.
7. Méthode suivant la revendication 6, dans laquelle le support solide pour l'acide nucléique est (a) un capillaire et l'acide nucléique est fixé par covalence à la paroi intérieure du capillaire ; ou (b) choisi dans le groupe consistant en des billes de verre, des billes de cellulose, des billes de polystyrène, des billes de Sephadex®, des billes de Sepharose®, des billes de polyacrylamide et des billes d'agarose ; ou (c) une membrane plate.
- 50 8. Méthode suivant l'une quelconque des revendications précédentes, dans laquelle l'acide nucléique comprend des nucléotides à masse modifiée.
- 55 9. Méthode suivant l'une quelconque des revendications 1 à 8, dans laquelle lesdits nucléotides libérés de manière séquentielle sont soumis à une modification de masse après la libération avec l'exonuclease et avant l'identification par spectrométrie de masse.

10. Méthode suivant la revendication 9, dans laquelle la libération séquentielle est effectuée par mise en contact avec une phosphatase alcaline.
- 5 11. Méthode suivant la revendication 8, dans laquelle les nucléotides à masse modifiée modulent le taux de l'activité d'exonucléase.
12. Méthode suivant l'une quelconque des revendications précédentes, dans laquelle i types différents d'acides nucléiques sont séquencés conjointement par séquençage par spectrométrie de masse multiplex et les nucléotides libérés de manière séquentielle de chaque type des i acides nucléiques peuvent être différenciés par spectrométrie de masse, des nucléotides libérés de manière séquentielle des i-1 acides nucléiques restants sur la base d'une différence de masse due à la modification de masse d'au moins une partie des nucléotides libérés de manière séquentielle.
- 10 13. Méthode suivant la revendication 12, dans laquelle les nucléotides à masse modifiée modulent le taux de l'activité d'exonucléase.
- 15 14. Méthode suivant la revendication 12, dans laquelle le nucléotide à masse modifiée comprend une fonctionnalité modificatrice de masse (M) fixée au nucléotide libéré de manière séquentielle.
- 20 15. Méthode suivant la revendication 12, dans laquelle (a) au moins un des nucléotides à masse modifiée est modifié avec une fonctionnalité modificatrice de masse (M) fixée à un phosphate 5' ; ou (b) au moins un des nucléotides à masse modifiée est modifié avec une fonctionnalité modificatrice de masse (M) fixée à une position C-2' d'un groupement sucre ; ou (c) au moins un des nucléotides à masse modifiée est modifié avec une fonctionnalité modificatrice de masse (M) fixée à une base hétérocyclique.
- 25 16. Méthode suivant la revendication 15, dans laquelle le nucléotide à masse modifiée comprend une base hétérocyclique modifiée choisie dans le groupe consistant en un groupement cytosine modifié en position C-5, un groupement uracile modifié en position C-5, un groupement thymine modifié au niveau du groupe méthyle en position C-5, un groupement adénine modifié en position C-8, un groupement c7-déaza-adénine modifié en position C-8, un groupement c7-déaza-adénine modifié en position C-7, un groupement guanine modifié en position C-8, un groupement c-7-déazaguanine modifié en position C-8, un groupement c7-déazaguanine modifié en position C-7, un groupement hypoxanthine modifié en position C-8, un groupement c7-déazahypoxanthine modifié en position C-8 et un groupement c7-déazahypoxanthine modifié en position C-7.
- 30 17. Méthode suivant la revendication 8, dans laquelle l'acide nucléique à masse modifiée est préparé à partir d'un polynucléotide monocaténaire servant de matrice complémentaire de la séquence d'acide nucléique par synthèse de l'acide nucléique en utilisant des nucléotides à masse modifiée.
- 35 18. Méthode suivant la revendication 17, dans laquelle (a) l'acide nucléique à masse modifiée est synthétisé en utilisant une ADN-polymérase et des désoxynucléoside-triphosphates (dNTP) à masse modifiée ; ou (b) l'acide nucléique à masse modifiée est synthétisé en utilisant une ARN-polymérase et des ribonucléoside-triphosphates (NTP) à masse modifiée.
- 40 19. Méthode suivant la revendication 17, dans laquelle (a) l'acide nucléique à masse modifiée est synthétisé en utilisant une amorce ayant une séquence qui permet l'ancrage de l'acide nucléique au support solide ; ou (b) la synthèse de l'acide nucléique est déclenchée en présence d'un oligonucléotide initiateur ayant une fonctionnalité 5' permettant l'immobilisation de l'acide nucléique sur le support solide.
- 45 20. Méthode suivant la revendication 6, dans laquelle l'acide nucléique comprend en outre un groupe de liaison (L) pour la fixation covalente de l'acide nucléique au support solide.
- 50 21. Méthode suivant la revendication 20, dans laquelle le support solide comprend en outre un oligonucléotide d'attelle et le groupe de liaison (L) comprend une séquence de nucléotides apte à l'annelage à l'oligonucléotide d'attelle et la fixation covalente au support solide sous l'action d'une activité de ligase.
- 55 22. Kit pour le séquençage d'acides nucléiques par spectrométrie de masse à médiation par exonucléase, comprenant
  - (i) une activité d'exonucléase pour le clivage des acides nucléiques unilatéralement à partir d'une première



extrémité pour libérer de manière séquentielle des nucléotides distincts ;  
 (ii) une série de nucléotides pour la synthèse de l'acide nucléique ;  
 (iii) une polymérase pour la synthèse de l'acide nucléique à partir d'une matrice complémentaire et de la série de nucléotides ; et  
 5 (iv) un support solide pour l'immobilisation de l'acide nucléique ou de l'exonucléase,

dans lequel au moins une partie de la série de nucléotides est soumise à une modification de masse pour moduler l'activité de clivage de l'exonucléase.

- 10 23. Kit suivant la revendication 22, dans lequel les acides nucléiques comprennent en outre au moins deux types différents d'acide nucléique.
24. Kit suivant la revendication 22 ou 23, dans lequel les acides nucléiques sont des acides 2'-désoxyribonucléiques (ADN) ou des acides ribonucléiques (ARN).
- 15 25. Kit suivant la revendication 22, 23 ou 24, dans lequel l'activité d'exonucléase est choisie dans le groupe consistant en la phosphodiastérase de venin de serpent, la phosphodiastérase de rate, la nucléase Bal-31, l'exonucléase I de *E. coli*, l'exonucléase VII de *E. coli*, la nucléase de haricot Mung, la nucléase S1, une activité d'exonucléase d'ADN-polymérase I de *E. coli*, une activité d'exonucléase d'un fragment de Klenow d'ADN-polymérase I, une  
 20 activité d'exonucléase d'ADN-polymérase T4, une activité d'exonucléase d'ADN-polymérase T7, une activité d'exonucléase d'ADN-polymérase Taq, une activité d'exonucléase d'ADN-polymérase Deep Vent®, l'exonucléase, l'exonucléase III et une activité d'exonucléase d'ADN-polymérase Vent®.
26. Kit suivant l'une quelconque des revendications 22 à 25, dans lequel le support solide est choisi dans le groupe consistant en un capillaire, une membrane plate, des billes de verre, des billes de cellulose, des billes de polystyrène, des billes de Sephadex®, des billes de Sepharose®, des billes de polyacrylamide et des billes d'agarose.
- 25 27. Kit suivant l'une quelconque des revendications 22 à 26, dans lequel le support solide est fonctionnalisé pour faciliter la fixation covalente des acides nucléiques.
- 30 28. Kit suivant l'une quelconque des revendications 22 à 27, dans lequel l'activité d'exonucléase est immobilisée par fixation covalente au support solide.
29. Kit suivant l'une quelconque des revendications 22 à 28, dans lequel le nucléotide à masse modifiée comprend une fonctionnalité modificatrice de masse (M) fixée à un groupement nucléotidique.
- 35 30. Kit suivant la revendication 29, dans lequel la fonctionnalité modificatrice de masse (M) est fixée à un groupement nucléotidique à une position choisie dans le groupe consistant en un phosphate 5', une position C-2' d'un groupement sucre et une base hétérocyclique.
- 40 31. Kit suivant l'une quelconque des revendications 22 à 30, comprenant en outre un manuel d'instruction indiquant le protocole de séquençage par l'exonucléase.
32. Kit suivant l'une quelconque des revendications 22 à 31, dans lequel au moins une partie de la série de nucléotides  
 45 est soumise à une modification de masse de telle sorte que les nucléotides libérés de manière séquentielle de chacun des types différents soient différenciables.
33. Méthode pour déterminer une séquence d'un acide nucléique, comprenant les étapes consistant
- 50 (i) à isoler l'acide nucléique à séquencer ;  
 (ii) à cliver l'acide nucléique unilatéralement à partir d'une première extrémité avec une activité d'exonucléase pour produire une série de fragments d'acide nucléique ;  
 (iii) à identifier la valeur de poids moléculaire de chaque fragment de la série de fragments d'acide nucléique par spectrométrie de masse ; et  
 55 (iv) à déterminer la séquence de l'acide nucléique d'après les valeurs de poids moléculaires de la série de fragments d'acide nucléique ; dans laquelle l'acide nucléique isolé est immobilisé par fixation covalente à un support solide.

34. Méthode suivant la revendication 33, dans laquelle l'acide nucléique est un acide 2'-désoxyribonucléique (ADN) ou un acide ribonucléique (ARN).
- 5 35. Méthode suivant la revendication 33 ou la revendication 34, dans laquelle l'activité d'exonucléase est choisie dans le groupe consistant en la phosphodiastérase de venin de serpent, la phosphodiastérase de rate, la nucléase Bal-31, l'exonucléase I de *E. coli*, l'exonucléase VII de *E. coli*, la nucléase de haricot Mung, la nucléase S1, une activité d'exonucléase d'ADN-polymérase I de *E. coli*, une activité d'exonucléase du fragment de Klenow d'ADN-polymérase I, une activité d'exonucléase d'ADN-polymérase T4, une activité d'exonucléase d'ADN-polymérase T7, une  
10 activité d'exonucléase d'ADN-polymérase Taq, une activité d'exonucléase d'ADN-polymérase Deep Vent®, l'exonucléase III, l'exonucléase et une activité d'exonucléase d'ADN-polymérase Vent®.
36. Méthode suivant l'une quelconque des revendications 33 à 35, dans laquelle l'acide nucléique comprend des nucléotides à masse modifiée.
- 15 37. Méthode suivant l'une quelconque des revendications 1 à 21 et 33 à 36, dans laquelle des molécules d'acide nucléique multiples sont clivées.
38. Système pour le séquençage par spectrométrie de masse à médiation par une exonucléase, comprenant  
20 (i) un moyen de réaction destiné à contenir les réactions de clivage par exonucléase des acides nucléiques cibles, la réaction de clivage formant une succession de nucléotides distincts libérés de manière séquentielle ;  
(ii) un moyen de spectrométrie de masse pour détecter la succession de nucléotides distincts libérés par le clivage par exonucléase de l'acide nucléique cible ; et  
(iii) un moyen de transfert pour transférer la succession de nucléotides distincts du moyen de réaction au  
25 moyen de spectrométrie de masse.
39. Système suivant la revendication 38, dans lequel le moyen de transfert comprend en outre une bande transporteuse.
- 30 40. Système suivant la revendication 38 ou la revendication 39, dans lequel le moyen de réaction comprend en outre un réacteur avec une enveloppe de refroidissement/chauffage pour la régulation de la température dans la réaction de clivage par exonucléase, au moins un ballon de réactif pour fournir au moins un réactif au réacteur, au moins un dispositif de pompage pour le pompage des réactifs et des corps réactionnels au et hors du réacteur, au moins un serpentin de chauffage/refroidissement pour réguler la température des réactifs fournis au réacteur et un moyen  
35 pour immobiliser un des acides nucléiques cibles ou l'exonucléase dans le réacteur.
41. Système suivant la revendication 39, dans lequel la bande transporteuse comprend une bande transporteuse sans fin commandée par un moteur pas à pas et maintenue sous tension par des poulies chargées par ressort, une zone d'application d'échantillon pour l'application d'un échantillon des nucléotides distincts libérés par le clivage  
40 par exonucléase des acides nucléiques cibles à une partie de la bande transporteuse, une plaque de refroidissement/chauffage positionnée au-dessous de la zone d'application d'échantillon ou régulant la température de la zone d'application d'échantillon, une caméra CCD avec une optique pour examiner la zone d'application d'échantillon, une source d'ionisation/désorption capable de se déplacer sur la surface de la bande dans une direction perpendiculaire au mouvement de la bande transporteuse, des étages de pompage différentiels de mise sous vide  
45 pour engendrer un vide sur une partie de la bande transporteuse, et un dispositif de chauffage pour faciliter l'élimination du résidu d'échantillon de la bande transporteuse.
42. Système suivant la revendication 41, (a) comprenant en outre un poste de lavage pour laver la bande transporteuse avec une solution nettoyante avant l'application de l'échantillon, le dispositif de chauffage facilitant le séchage de  
50 la bande après rinçage avec la solution nettoyante ; ou (b) dans lequel le dispositif de chauffage consiste en un dispositif à micro-ondes ; ou (c) dans lequel la source d'ionisation/désorption est un laser.
43. Système suivant l'une quelconque des revendications 38 à 42, comprenant en outre (a) une pluralité de moyens de réaction pour le séquençage en parallèle d'une pluralité d'acides nucléiques ; ou (b) un microprocesseur pour  
55 le traitement de la succession détectée de nucléotides libérés et pour la détermination de la séquence des acides nucléiques cibles.
44. Système suivant la revendication 40, dans lequel le moyen de réaction comprend en outre au moins un réacteur

secondaire pour la modification de la masse des nucléotides distincts libérés par le clivage par exonuclease des acides nucléiques cibles.

- 5 45. Système suivant la revendication 44, dans lequel le réacteur secondaire comprend de la phosphatase alcaline immobilisée.

**Revendications pour les Etats contractants suivants : NL, BE, AT, LU, ES, GR, DK, MC, PT, IE**

- 10 1. Méthode pour la détermination d'une séquence d'un acide nucléique, comprenant les étapes consistant
- (i) à isoler l'acide nucléique à séquencer ;
  - (ii) à cliver l'acide nucléique unilatéralement par une première extrémité avec une activité d'exonuclease pour libérer de manière séquentielle des nucléotides distincts ;
  - 15 (iii) à identifier chacun des nucléotides libérés de manière séquentielle par spectrométrie de masse ; et
  - (iv) à déterminer la séquence de l'acide nucléique d'après les nucléotides identifiés.
2. Méthode suivant la revendication 1, dans laquelle l'acide nucléique est un acide 2'-désoxyribonucléique (ADN) ou un acide ribonucléique (ARN).
- 20 3. Méthode suivant la revendication 1 ou la revendication 2, dans laquelle l'activité d'exonuclease est choisie dans le groupe consistant en la phosphodiesterase de venin de serpent, la phosphodiesterase de rate, la nucléase Bal-31, l'exonuclease I de *E. coli*, l'exonuclease VII de *E. coli*, la nucléase de haricot Mung, la nucléase S1, une activité d'exonuclease d'ADN-polymérase I de *E. coli*, une activité d'exonuclease d'un fragment de Klenow d'ADN-polymérase I, une activité d'exonuclease d'ADN-polymérase T4, une activité d'exonuclease d'ADN-polymérase de T7, une activité d'exonuclease d'ADN-polymérase Taq, une activité d'exonuclease d'ADN-polymérase Deep Vent®, l'exonuclease III et une activité d'exonuclease d'ADN-polymérase Vent®.
- 25 4. Méthode suivant l'une quelconque des revendications 1, 2 et 3, dans laquelle l'activité d'exonuclease est immobilisée par fixation covalente à un support solide, pléageage dans une matrice de gel ou introduction dans un réacteur muni d'une membrane semi-perméable.
- 30 5. Méthode suivant la revendication 4, dans laquelle le support solide pour l'activité d'exonuclease est (a) un capillaire et l'activité d'exonuclease est fixée par covalence à la paroi intérieure du capillaire ; ou (b) choisi dans le groupe consistant en des billes de verre, des billes de cellulose, des billes de polystyrène, des billes de Sephadex®, des billes de Sepharose®, des billes de polyacrylamide et des billes d'agarose ; et (c) une membrane plate.
- 35 6. Méthode suivant l'une quelconque des revendications 1, 2 et 3, dans laquelle l'acide nucléique isolé est immobilisé par fixation covalente à un support solide et l'activité d'exonuclease est présente dans une solution en contact avec l'acide nucléique immobilisé.
- 40 7. Méthode suivant la revendication 6, dans laquelle le support solide pour l'acide nucléique est (a) un capillaire et l'acide nucléique est fixé par covalence à la paroi intérieure du capillaire ; ou (b) choisi dans le groupe consistant en des billes de verre, des billes de cellulose, des billes de polystyrène, des billes de Sephadex®, des billes de Sepharose®, des billes de polyacrylamide et des billes d'agarose ; ou (c) une membrane plate.
- 45 8. Méthode suivant l'une quelconque des revendications précédentes, dans laquelle l'acide nucléique comprend des nucléotides à masse modifiée.
- 50 9. Méthode suivant l'une quelconque des revendications 1 à 8, dans laquelle lesdits nucléotides libérés de manière séquentielle sont soumis à une modification de masse après la libération avec l'exonuclease et avant l'identification par spectrométrie de masse.
- 55 10. Méthode suivant la revendication 9, dans laquelle la libération séquentielle est effectuée par mise en contact avec la phosphatase alcaline.
11. Méthode suivant la revendication 8, dans laquelle les nucléotides à masse modifiée modulent le taux de l'activité d'exonuclease.

12. Méthode suivant l'une quelconque des revendications précédentes, dans laquelle i types différents d'acides nucléiques sont séquencés conjointement par séquençage par spectrométrie de masse multiplex et les nucléotides libérés de manière séquentielle de chaque type des i acides nucléiques peuvent être différenciés par spectrométrie de masse, des nucléotides libérés de manière séquentielle des i-1 acides nucléiques restants sur la base d'une différence de masse due à la modification de masse d'au moins une partie des nucléotides libérés de manière séquentielle.
13. Méthode suivant la revendication 12, dans laquelle les nucléotides à masse modifiée modulent le taux de l'activité d'exonucléase.
14. Méthode suivant la revendication 12, dans laquelle le nucléotide à masse modifiée comprend une fonctionnalité modificatrice de masse (M) fixée au nucléotide libéré de manière séquentielle.
15. Méthode suivant la revendication 12, dans laquelle (a) au moins un des nucléotides à masse modifiée est modifié avec une fonctionnalité modificatrice de masse (M) fixée à un phosphate 5' ; ou (b) au moins un des nucléotides à masse modifiée est modifié avec une fonctionnalité modificatrice de masse (M) fixée à une position C-2' d'un groupement sucre ; ou (c) au moins un des nucléotides à masse modifiée est modifié avec une fonctionnalité modificatrice de masse (M) fixée à une base hétérocyclique.
16. Méthode suivant la revendication 15, dans laquelle le nucléotide à masse modifiée comprend une base hétérocyclique modifiée choisie dans le groupe consistant en un groupement cytosine modifié en position C-5, un groupement uracile modifié en position C-5, un groupement thymine modifié au niveau du groupe méthyle en position C-5, un groupement adénine modifié en position C-8, un groupement c7-déaza-adénine modifié en position C-8, un groupement c7-déaza-adénine modifié en position C-7, un groupement guanine modifié en position C-8, un groupement c-7-déazaguanine modifié en position C-8, un groupement c7-déazaguanine modifié en position C-7, un groupement hypoxanthine modifié en position C-8, un groupement c7-déazahypoxanthine modifié en position C-8 et un groupement c7-déazahypoxanthine modifié en position C-7.
17. Méthode suivant la revendication 8, dans laquelle l'acide nucléique à masse modifiée est préparé à partir d'un polynucléotide monocaténaire servant de matrice complémentaire de la séquence d'acide nucléique par synthèse de l'acide nucléique en utilisant des nucléotides à masse modifiée.
18. Méthode suivant la revendication 17, dans laquelle (a) l'acide nucléique à masse modifiée est synthétisé en utilisant une ADN-polymérase et des désoxyribonucléoside-triphosphates (dNTP) à masse modifiée ; ou (b) l'acide nucléique à masse modifiée est synthétisé en utilisant une ARN-polymérase et des ribonucléoside-triphosphates (NTP) à masse modifiée.
19. Méthode suivant la revendication 17, dans laquelle (a) l'acide nucléique à masse modifiée est synthétisé en utilisant une amorce ayant une séquence qui permet l'ancrage de l'acide nucléique au support solide ; ou (b) la synthèse de l'acide nucléique est déclenchée en présence d'un oligonucléotide initiateur ayant une fonctionnalité 5' permettant l'immobilisation de l'acide nucléique sur le support solide.
20. Méthode suivant la revendication 6, dans laquelle l'acide nucléique comprend en outre un groupe de liaison (L) pour la fixation covalente de l'acide nucléique au support solide.
21. Méthode suivant la revendication 20, dans laquelle le support solide comprend en outre un oligonucléotide d'attelle et le groupe de liaison (L) comprend une séquence de nucléotides apte à l'annelage à l'oligonucléotide d'attelle et à la fixation covalente au support solide sous l'action d'une activité de ligase.
22. Kit pour le séquençage d'acides nucléiques par spectrométrie de masse à médiation par exonucléase, comprenant
  - (i) une activité d'exonucléase pour le clivage des acides nucléiques unilatéralement à partir d'une première extrémité pour libérer de manière séquentielle des nucléotides distincts ;
  - (ii) une série de nucléotides pour la synthèse de l'acide nucléique ;
  - (iii) une polymérase pour la synthèse de l'acide nucléique à partir d'une matrice complémentaire et de la série de nucléotides ; et
  - (iv) un support solide pour l'immobilisation de l'acide nucléique ou de l'exonucléase,



dans lequel au moins une partie de la série de nucléotides est soumise à une modification de masse pour moduler l'activité de clivage de l'exonucléase.

23. Kit suivant la revendication 22, dans lequel les acides nucléiques comprennent en outre au moins deux types différents d'acide nucléique.
24. Kit suivant la revendication 22 ou 23, dans lequel les acides nucléiques sont des acides 2'-désoxyribonucléiques (ADN) ou des acides ribonucléiques (ARN).
25. Kit suivant la revendication 22, 23 ou 24, dans lequel l'activité d'exonucléase est choisie dans le groupe consistant en la phosphodiastérase de venin de serpent, la phosphodiastérase de rate, la nucléase Bal-31, l'exonucléase I de *E. coli*, l'exonucléase VII de *E. coli*, la nucléase de haricot Mung, la nucléase S1, une activité d'exonucléase d'ADN-polymérase I de *E. coli*, une activité d'exonucléase d'un fragment de Klenow d'ADN-polymérase I, une activité d'exonucléase d'ADN-polymérase T4, une activité d'exonucléase d'ADN-polymérase T7, une activité d'exonucléase d'ADN-polymérase Taq, une activité d'exonucléase d'ADN-polymérase Deep Vent®, l'exonucléase, l'exonucléase III et une activité d'exonucléase d'ADN-polymérase Vent®.
26. Kit suivant l'une quelconque des revendications 22 à 25, dans lequel le support solide est choisi dans le groupe consistant en un capillaire, une membrane plate, des billes de verre, des billes de cellulose, des billes de polystyrène, des billes de Sephadex®, des billes de Sepharose®, des billes de polyacrylamide et des billes d'agarose.
27. Kit suivant l'une quelconque des revendications 22 à 26, dans lequel le support solide est fonctionnalisé pour faciliter la fixation covalente des acides nucléiques.
28. Kit suivant l'une quelconque des revendications 22 à 27, dans lequel l'activité d'exonucléase est immobilisée par fixation covalente au support solide.
29. Kit suivant l'une quelconque des revendications 22 à 28, dans lequel le nucléotide à masse modifiée comprend une fonctionnalité modificatrice de masse (M) fixée à un groupement nucléotidique.
30. Kit suivant la revendication 29, dans lequel la fonctionnalité modificatrice de masse (M) est fixée à un groupement nucléotidique à une position choisie dans le groupe consistant en un phosphate 5', une position C-2' d'un groupement sucre et une base hétérocyclique.
31. Kit suivant l'une quelconque des revendications 22 à 30, comprenant en outre un manuel d'instruction indiquant le protocole de séquençage par l'exonucléase.
32. Kit suivant l'une quelconque des revendications 22 à 31, dans lequel au moins une partie de la série de nucléotides est soumise à une modification de masse de telle sorte que les nucléotides libérés de manière séquentielle de chacun des types différents soient différenciables.
33. Méthode pour déterminer une séquence d'un acide nucléique, comprenant les étapes consistant
  - (i) à isoler l'acide nucléique à séquencer ;
  - (ii) à cliver l'acide nucléique unilatéralement à partir d'une première extrémité avec une activité d'exonucléase pour produire une série de fragments d'acide nucléique ;
  - (iii) à identifier la valeur de poids moléculaire de chaque fragment de la série de fragments d'acide nucléique par spectrométrie de masse ; et
  - (iv) à déterminer la séquence de l'acide nucléique d'après les valeurs de poids moléculaires de la série de fragments d'acide nucléique ; dans laquelle l'acide nucléique isolé est immobilisé par fixation covalente à un support solide.
34. Méthode suivant la revendication 33, dans laquelle l'acide nucléique est un acide 2'-désoxyribonucléique (ADN) ou un acide ribonucléique (ARN).
35. Méthode suivant la revendication 33 ou la revendication 34, dans laquelle l'activité d'exonucléase est choisie dans le groupe consistant en la phosphodiastérase de venin de serpent, la phosphodiastérase de rate, la nucléase Bal-31, l'exonucléase I de *E. coli*, l'exonucléase VII de *E. coli*, la nucléase de haricot Mung, la nucléase S1, une activité

d'exonucléase d'ADN-polymérase I de *E. coli*, une activité d'exonucléase du fragment de Klenow d'ADN-polymérase I, une activité d'exonucléase d'ADN-polymérase T4, une activité d'exonucléase d'ADN-polymérase T7, une activité d'exonucléase d'ADN-polymérase Taq, une activité d'exonucléase d'ADN-polymérase Deep Vent®, l'exonucléase III, l'exonucléase et une activité d'exonucléase d'ADN-polymérase Vent®.

5

36. Méthode suivant l'une quelconque des revendications 33 à 35, dans laquelle l'acide nucléique comprend des nucléotides à masse modifiée.

10

37. Méthode suivant l'une quelconque des revendications 1 à 21 et 33 à 36, dans laquelle des molécules d'acide nucléique multiples sont clivées.

38. Système pour le séquençage par spectrométrie de masse à médiation par exonucléase, comprenant

15

- (i) un moyen de réaction destiné à contenir les réactions de clivage par exonucléase des acides nucléiques cibles, la réaction de clivage formant une succession de nucléotides distincts libérés de manière séquentielle ;
- (ii) un moyen de spectrométrie de masse pour détecter la succession de nucléotides distincts libérés par le clivage par exonucléase de l'acide nucléique cible ; et
- (iii) un moyen de transfert pour transférer la succession de nucléotides distincts du moyen de réaction au moyen de spectrométrie de masse.

20

39. Système suivant la revendication 38, dans lequel le moyen de transfert comprend en outre une bande transporteuse.

25

40. Système suivant la revendication 38 ou la revendication 39, dans lequel le moyen de réaction comprend en outre un réacteur avec une enveloppe de refroidissement/chauffage pour la régulation de la température dans la réaction de clivage par exonucléase, au moins un ballon de réactif pour fournir au moins un réactif au réacteur, au moins un dispositif de pompage pour le pompage des réactifs et des corps réactionnels au et hors du réacteur, au moins un serpentin de chauffage/refroidissement pour réguler la température des réactifs fournis au réacteur et un moyen pour immobiliser un des acides nucléiques cibles ou l'exonucléase dans le réacteur.

30

41. Système suivant la revendication 39, dans lequel la bande transporteuse comprend une bande transporteuse sans fin commandée par un moteur pas à pas et maintenue sous tension par des poulies chargées par ressort, une zone d'application d'échantillon pour l'application d'un échantillon des nucléotides distincts libérés par le clivage par exonucléase des acides nucléiques cibles à une partie de la bande transporteuse, une plaque de refroidissement/chauffage positionnée au-dessous de la zone d'application d'échantillon ou régulant la température de la zone d'application d'échantillon, une caméra CCD avec une optique pour examiner la zone d'application d'échantillon, une source d'ionisation/désorption capable de se déplacer sur la surface de la bande dans une direction perpendiculaire au mouvement de la bande transporteuse, des étages de pompage différentiels de mise sous vide pour engendrer un vide sur une partie de la bande transporteuse, et un dispositif de chauffage pour faciliter l'élimination du résidu d'échantillon de la bande transporteuse.

35

40

42. Système suivant la revendication 41, (a) comprenant en outre un poste de lavage pour laver la bande transporteuse avec une solution nettoyante avant l'application de l'échantillon, le dispositif de chauffage facilitant le séchage de la bande après rinçage avec la solution nettoyante ; ou (b) dans lequel le dispositif de chauffage consiste en un dispositif à micro-ondes ; ou (c) dans lequel la source d'ionisation/désorption est un laser.

45

43. Système suivant l'une quelconque des revendications 38 à 42, comprenant en outre (a) une pluralité de moyens de réaction pour le séquençage en parallèle d'une pluralité d'acides nucléiques ; ou (b) un microprocesseur pour le traitement de la succession détectée de nucléotides libérés et pour la détermination de la séquence des acides nucléiques cibles.

50

44. Système suivant la revendication 40, dans lequel le moyen de réaction comprend en outre au moins un réacteur secondaire pour la modification de la masse des nucléotides distincts libérés par le clivage par exonucléase des acides nucléiques cibles.

55

45. Système suivant la revendication 44, dans lequel le réacteur secondaire comprend de la phosphatase alcaline immobilisée.

**EP 0 689 610 B1**

**46. Méthode pour déterminer une séquence d'un acide nucléique, comprenant les étapes consistant :**

- (i) à isoler l'acide nucléique à séquencer ;**
- (ii) à cliver l'acide nucléique unilatéralement par une première extrémité avec une activité d'exonucléase pour produire une série de fragments d'acide nucléique emboîtés ;**
- (iii) à identifier la valeur de poids moléculaire de chaque fragment de la série de fragments d'acide nucléique par spectrométrie de masse ; et**
- (iv) à déterminer la séquence de l'acide nucléique à partir des valeurs de poids moléculaire de la série de fragments d'acide nucléique.**

5

10

15

20

25

30

35

40

45

50

55

FIG. 1






FIG. 2




FIG. 3




FIG. 4A




FIG. 4B















FIG. 5



$n = 1 - 1000$   
 $M = H, OH, XR,$   
 Halogen,  $N_3$



FIG. 6



M = H, OH, XR,  
Halogen, N<sub>3</sub>

## FIG. 7

Mass modifying functionality R (X similar to FIGURE 8):

H

Alkyl:  $-(CH_2)_r-CH_3$  e.g.  $-CH_3$ ,  $-C_2H_5$ ,  
and branched e.g.  $-CH(CH_3)_2$  $ICH_2(CH_2)_r-O-H$ 

2,3-Epoxy-1-propanol

 $-(CH_2)_m-CH_2-O-H$  $-(CH_2)_m-CH_2-O-Alkyl$  $-(CH_2CH_2NH)_m-CH_2CH_2-NH_2$  $-[NH-(CH_2)_r-NH-C(=O)-(CH_2)_r-C(=O)]_m-NH-(CH_2)_r-NH-C(=O)-(CH_2)_r-C(=O)-OH$  $-[NH(CH_2)_r-C(=O)]_m-NH-(CH_2)_r-C(=O)-OH$  $-[NH-CHY-C(=O)]_m-NH-CHY-C(=O)-OH$  $-[O-(CH_2)_r-C(=O)]_m-O-(CH_2)_r-C(=O)-OH$  $-S-$  $-Si(Alkyl)_3$  $-Halogen$  $-N_3$  $-CH_2F$ ,  $-CHF_2$ ,  $-CF_3$  $m = 0, 1 - 200$  $r = 1 - 20$

FIG. 8

x
-O-
-O-C-(CH <sub>2</sub> ) <sub>r</sub> -C-O-
-NH-C-/C-NH-
-NH-C-(CH <sub>2</sub> ) <sub>r</sub> -C-O-
-NH-C-NH-
-O-P-O-Alkyl
-O-SO <sub>2</sub> -O-
-O-C-CH <sub>2</sub> -S-
-S-
-NH-
m = 0, 1 - 200 r = 1 - 20

FIG. 9






FIG. 10





FIG. II



**FIG. 12**




FIG. 13






FIG. 14A





FIG. 14B



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**